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Alcohol use disorder (AUD) represent a major health problem worldwide. Despite the severe 
consequences of AUD, only four medications are approved in Sweden for this disease. In 
addition, the prescription rates are low, partly due to varying clinical efficacy of these 
medications. Consequently, new, more effective pharmacotherapies are needed. A main 
problem in the treatment of AUD is the long-lasting vulnerability to relapse. Relapse is 
typically triggered by: stress, acute exposure to the drug, or drug-associated cues or context. 
Impaired impulsive control, often seen in AUD individuals, might further contributes to 
relapse to alcohol drinking. The dopamine (DA) system is one possible treatment target for 
AUD.  Dopamine D2 receptors has been suggested to be involved in mediating alcohol’s 
reinforcing properties and a decrease in DA release and a reduction in D2 receptors have been 
found in detoxified AUD patients. This DA down-regulation is hypothesized to induce 
alcohol craving and contribute to relapse even after a long period of abstinence. In addition to 
the role of DA in AUD, DA has also been suggested to be involved in impulse behavior. The 
monoamine stabilizer (-)-OSU6162 (OSU6162) has the ability to stimulate, inhibit, or show 
no effect on DA-related behaviors depending upon the prevailing dopaminergic tone. In this 
thesis, we evaluated the potential of OSU6162 as a new treatment for AUD using validated 
preclinical models of behaviors related to AUD. We have, in this thesis, identified OSU6162 
as a potential novel treatment for AUD. Using a battery of animal models, we showed that 
OSU6162 attenuated voluntary alcohol intake, alcohol withdrawal symptoms (tail stiffness 
and walking with broad gait), the motivation to seek alcohol, cue/priming-induced 
reinstatement (relapse) of alcohol seeking, and relapse-like drinking in in rats that had been 
drinking alcohol for a long period of time. Moreover, we showed that OSU6162 pre-
treatment improved motor impulsivity in both alcohol and alcohol-naïve rats. Furthermore, 
OSU6162 did not induce conditioned place preference in either alcohol-naïve rats or rats that 
had been drinking alcohol before the experiment, indicating that OSU6162 does not possess 
any abuse liability on its own. Together these results highlights OSU6162’s potential to 
prevent relapse triggered by alcohol craving, alcohol related cues, re-exposure to alcohol and 
or an urge to relieve abstinence symptoms. In addition, the improved impulse control 
following OSU6162 treatment might help AUD individuals to override a compulsive drug-
taking behavior in response to craving and thereby possibly prevent relapse to alcohol 
drinking. In addition to the global health problems related to alcohol, an opioid addiction 
epidemic is ongoing in the United State. We therefore decided to examine the potential of 
OSU6162 to attenuate self-administration of the opioid oxycodone in rats. The results 
showed that OSU6162 attenuated operant oxycodone self-administration but had no effect on 
context-induced reinstatement, at least in the dose tested. These preliminary results indicate 
that OSU612 might have potential to decrease intake of oxycodone, however, further studies 
are needed to fully evaluate the potential of OSU6162 on oxycodone self-administration and 
reinstatement. In conclusion, the results in this thesis indicate that OSU6162 may serve as a 
novel treatment for AUD and provided the necessary rational for a clinical “proof-of-
concept” study with OSU6162 in alcohol dependent patients. The clinical study was 
  
successfully executed and supported our preclinical findings by showing that OSU6162 
attenuated alcohol craving in alcohol dependent patients. Thus, the rapid and fruitful 
transition of OSU6162 from bench to clinic highlights the importance of the preclinical 
medication development program used in this thesis work.    
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1 INTRODUCTION 
1.1 THE BURDEN AND COST OF ALCOHOL USE 
Alcohol is a psychoactive substance that is mainly consumed for its pleasurable effects. 
According to the World Health Organization (WHO), approximately 2 billion people 
worldwide consume alcohol beverages, and 76.3 million are suffering from alcohol use 
disorder (AUD) [1]. In 2012, 3.3 million deaths or 5.9% of all global deaths were associated 
with alcohol [2]. Moreover, alcohol is estimated to cause about 20–30% of vehicle accidents 
and homicides worldwide [1]. In addition, harmful alcohol use has been identified as a causal 
factor in numerous types of chronic diseases, such as AUD, cancers, cardiovascular diseases, 
diabetes, neuropsychiatric disorders, gastrointestinal diseases, and infectious diseases [1]. 
Globally, alcohol misuse has been listed by WHO as the fifth leading causes of morbidity and 
mortality and is responsible for 5.1% of the global disease burden [2].   
In Sweden, approximately one million people drink excessive amounts of alcohol risking 
negative health effects and, approximately 446 000 individuals or 5.9 % of the population 
suffer from alcohol dependence or alcohol misuse (according the DMS-IV) [3]. Besides 
devastating medical and psychiatric consequences for the AUD individual, AUD is a heavy 
burden to family, friends and social services, as well as an enormous economic burden for 
society. In Sweden alone, alcohol misuse and addiction costs society around 49 million SEK 
annually [4]. Despite the major health problem, only four medications are approved as a 
treatment for AUD in Sweden. However, the clinical efficacies of these are varying and 
limited [5]. Given the seriousness of AUD, new, more effective, medications are truly 
needed. 
1.2 ALCOHOL USE DISORDERS 
1.2.1 Diagnostic Criteria for AUD 
Alcohol use disorders is a chronic relapsing brain disease characterized by obsession of 
seeking and consuming alcohol despite negative consequences, loss of control in limiting the 
intake and emergence of a negative emotional state (e.g. dysphoria, anxiety, irritability) when 
alcohol is not on board [6]. Suffering from AUD is often seen by the society as a defect of 
character [7]. However, once established, AUD is a brain disorder that shares numerous 
characteristics with other chronical relapse medical conditions such as hypertension, diabetes 
and asthma [8]. Although, AUD cannot be treated without regards for its social and 
behavioral context, the same is also true for other chronic relapsing disorders. Thus, AUD 
should be viewed as a treatable disease, not as a character flaw. There is no biological marker 
for AUD. Instead clinicians use criterion-based diagnostic instruments. The International 
Classification of Diseases (ICD) system [9] and The Diagnostic and Statistical Manual of 
Mental Disorders (DSM) are both diagnostic instruments frequently used to diagnose AUD 
[6]. 
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Table. 1. Diagnostic criteria for AUD according to DSM-5. A minimum of two symptoms are required to 
diagnose an AUD. Alcohol use disorders can be classified as mild (two to three symptoms), moderate (four to 
five) or severe (6 or more).  Figure modified from [10]. 
Diagnostic Criteria for alcohol use disorders (AUD) 
1. Alcohol are often taken in larger amounts or over a longer period of time than intended. 
2. There is a persistent desire or unsuccessful efforts to cut down or control alcohol use. 
3. A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its       
effects. 
4. Craving, or a strong desire to use alcohol. 
5. Recurrent alcohol use resulting in failure to fulfill major role obligations at work, school or home. 
6. Continued alcohol use despite having persistent or recurrent social or interpersonal problems caused or 
exacerbated by the effects of alcohol. 
7. Important social, occupational or recreational activities are given up or reduced because of alcohol use. 
8. Recurrent alcohol use in situations in which it is physically hazardous. 
9. Continued use despite knowledge of having a persistent or recurrent physical or psychological problem that   
is likely to have been caused or exacerbated by alcohol. 
10. Tolerance, as defined by either of the following: 
(a) A need for markedly increased amounts of alcohol to achieve intoxication or desired effect. 
(b) Markedly diminished effect with continued use of the same amount of an alcohol. 
11.Withdrawal, as manifested by either of the following: 
(a) The characteristic alcohol withdrawal syndrome. 
(b) The same (or a closely related) substance are taken to relieve or avoid withdrawal symptoms. 
 
The DSM was introduced by the American Psychiatric Association in 1952 and provides 
standardized criteria for mental disorders. In 2013, the fifth edition of the DSM (DSM-5) was 
published [10], which includes several important differences from the prior edition, DSM-IV 
[6]. To receive a diagnosis of AUD, at least two of the 11 criteria (displayed in Table 1) must 
be met during the same 12-month period. In DSM–IV, alcohol abuse and alcohol dependence 
were described as two distinct disorders. In contrast, in the DSM-5, alcohol abuse and alcohol 
dependence are integrated into one single disorder called “alcohol use disorders - AUD”.  
Alcohol use disorders is then subdivided into “mild”, “moderate” and “severe” AUD, based 
on the number of criteria fulfilled. The presence of two or three symptoms corresponds to 
mild AUD, four to five to moderate AUD, and six or more indicate severe AUD. Two other 
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changes made in DSM-5 are the addition of a new criterion involving craving and the 
criterion in DMS-IV regarding legal problems is eliminated [10]. 
In DSM-5, the diagnostic criteria for AUD could be grouped in four blocks: impaired control, 
social impairment, risky use, and pharmacological criteria (see Table. 1). Criteria 1-4 describe 
impaired control over alcohol use, such as having problems limiting the alcohol drinking, 
consuming more alcohol over time than was intended and craving for alcohol or a strong 
desire to drink. Moreover, criteria 5-7 focus on social impairments from consuming alcohol 
and involve negative outcomes of alcohol use affecting social and professional life, as well as 
important activities the individual is willing to give up in favor of alcohol. Furthermore, 
criteria 8-9 describe the risky use of alcohol such as, a recurrent alcohol use in situations in 
which it is physically hazardous and continued alcohol consumption despite knowledge of its 
physical or psychological problems. The last two criteria 10-11, describe tolerance and 
withdrawal, respectively [10]. Tolerance is a hallmark of addiction that could be defined as a 
decreased, reinforced efficacy of alcohol following repeated alcohol administration [11]. 
Thus, tolerance will increase the minimum dose alcohol needed to produce the same effect. 
Tolerance also includes a lesser sensitivity to the motor-impairing [12] and metabolic effects 
[13] of alcohol.  Withdrawal occurs in absence of alcohol and is characterized as a great 
discomfort for the AUD individual. Some withdrawal symptoms are suggested to increase the 
motivation to seek and consume alcohol [14]. Alcohol withdrawal symptoms could be both 
physical (e.g. convulsion, sweating, and higher heart rate) and psychological (e.g. anxiety and 
dysphoria) [15, 16]. However, withdrawal is not necessary for a diagnosis but is highly 
associated with severe AUD [10]. 
1.2.2 Current Available Pharmacotherapies  
Despite AUD’s high prevalence and its multiple and serious consequences for patients and 
society, only four medications are approved for the treatment of AUD in Sweden: disulfiram, 
acamprosate, naltrexone and nalmefene. The same medications are approved in the United 
States, with the exception of nalmefene, which is not approved by the US Food and Drug 
Administration (FDA). Because all currently available medications have shown limited and 
varying clinical efficacy [5], new, more effective pharmacotherapies are truly needed. 
1.2.2.1 Disulfiram 
Disulfiram (Antabuse ®), FDA-approved for the treatment of AUD in 1949, was the first 
pharmacological treatment introduced on the market to treat AUD. Alcohol is metabolized in 
the liver, via the enzyme alcohol dehydrogenase, to acetaldehyde and then to acetate via the 
enzyme acetaldehyde dehydrogenase. Disulfiram works by blocking the metabolism of 
alcohol in the body. Specifically, disulfiram inhibits the degeneration of acetaldehyde to 
acetate by blocking the liver enzyme acetaldehyde dehydrogenase [17, 18]. This causes an 
accumulation of the toxic metabolite acetaldehyde which results in the development of a 
highly aversive state with symptoms such as sweating, flushing, headache, nausea and 
tachycardia [18, 19]. The accumulation of acetaldehyde following alcohol consumption may 
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also have toxic effects on several organ systems, including the liver [20]. The fear of 
provoking an unpleasant disulﬁram-alcohol reaction [19] is believed to be the primary 
mechanism to facilitate abstinence from alcohol [7]. 
1.2.2.2 Naltrexone 
Naltrexone (Revia®, Vivitrol®), is primarily an antagonist at the μ-opioid receptors, but also 
at the opioid κ- and δ-receptors. Although, naltrexone’s mechanism of action is not 
completely understood, naltrexone most likely modulates the mesolimbic DA release induced 
by alcohol administration through interactions with the opioid system and thereby possibly 
decreasing the acute positive reinforcing properties of alcohol [7]. Indeed, a study has shown 
that mice lacking the μ-receptor do not self-administer alcohol [21]. 
Naltrexone was approved for the treatment of AUD by the FDA in 1994. The approval was 
based on initial clinical studies showing clinical evidence for efficacy for naltrexone in 
recently abstinent AUD individuals. Specifically, AUD individuals treated with naltrexone 
(50 mg/day) were less likely to relapse during the treatment period of 12 weeks compare to 
AUD individuals who received placebo [22, 23]. Nevertheless, 5 months after the treatment, 
the relapse rates for the naltrexone and placebo groups were similar. These early clinical 
studies were based on preclinical studies showing effect of naltrexone on alcohol 
consumption in rats [24]. Thus, preclinical studies have contributed to the approval of this 
agent, pointing to the beneficial effect of using preclinical studies in the development of new 
potential medications for AUD.  
Generally, the efficacy and safety of naltrexone is well documented [25, 26], however, some 
mixed results do exist [27]. The different response to naltrexone might have a genetic 
explanation, where individuals carrying a specific variant of the gene encoding the μ-opioid 
receptor (OPRM1), might respond better to naltrexone [28]. Additionally, it has also been 
suggested that individuals with high levels of craving for alcohol or have a family history of 
AUD [28, 29] are more likely to benefit from naltrexone treatment [29]. 
More recently, in 2006, depot formulation of naltrexone was approved by the FDA and has 
showed evidence for clinical efficacy [30]. Depot formulations of naltrexone may offer some 
advantages over oral formulations such as increased compliance, a variable reported to be 
critical in determining the success of naltrexone treatment [31]. 
1.2.2.3 Acamprosate 
Acamprosate (Campral®) was approved by the FDA in 2004, and is thereby the newest 
medication approved for treatment of AUD in US. Acamprosate has been shown to decrease 
craving and withdrawal distress in AUD individuals [32].  Acamprosate’s exact mechanism 
of action is still not fully understood. Because the chemical structure of acamprosate is 
similar to γ-aminobutyric acid (GABA), acamprostate was initially believed to be a 
GABAergic acting drug.  [33, 34]. However, later, acamprosate was demonstrated to rather 
act on NMDA receptor [35] and /or metabotropic-5 glutamate receptors [36] that may 
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modulate the hyperglutamatergic state associated with alcohol withdrawal. Evidence from a 
human magnetic resonance imaging study support acamprosate’s ability to modulate 
glutamate neurotransmission as it suppressed central glutamate over 4 weeks of treatment 
[37]. However, recently, another mechanism of action was suggested, namely that calcium is 
the active moiety of acamprosate (calcium-bis(N-acetylhomotaurinate)) and that N-
acetylhomotaurinate is a biologically inactive molecule [38], yet the mechanism of action is 
under debate. 
Clinically, multiple trials have shown that acamprosate added to psychosocial interventions 
improved the duration and rate of abstinence [39, 40], whereas other trials have failed to find 
efficacy for acamprosate [41, 42]. However, recently, two meta-analyses showed a small 
overall positive treatment efficacy, particularly when abstinence was the treatment goal [43, 
44]. 
1.2.2.4 Nalmefene 
Nalmefene (Selincro®) was approved by the European Medicines Agency to treat AUD in 
2013, but is not approved by the FDA. In contrast to disulfiram, naltrexone, and acamprosate 
which all are approved as an aid to maintain total abstinence, nalmefene is approved for the 
indication of reducing alcohol consumption. In addition, nalmefene is recommended to be 
used “as needed”, meaning that the patient could take nalmefene in preparation for a situation 
with a perceived heightened risk of drinking.  
Nalmefene is an opioid antagonist similar in both structure and activity to the opioid 
antagonist naltrexone. However, unlike naltrexone, nalmefene has shown no dose-dependent 
liver toxicity [45]. Moreover, nalmefene differ from naltrexone due to its partial agonist 
activity at the kappa-opioid receptor [46]. Multicenter clinical trials, in which nalmefene has 
been taken “as needed” in combination with psychosocial management, have reported 
efficacy of nalmefene in reducing alcohol consumption compared to placebo in alcohol 
dependent patients [47, 48]. 
1.2.3 Development of AUD 
Chronic alcohol use might over time lead to AUD. The development of AUD might be 
viewed as a cycle of spiraling dysregulation of brain reward systems that progressively 
increases, resulting in compulsive alcohol use and a loss of control over alcohol drinking 
[49]. The brain is a highly reactive organ, which rapidly responds and adapts to its 
surroundings. Chronic intoxication of alcohol produces multiple neuroadaptions at the 
cellular, molecular and neurocircuitry levels that eventually may lead to the transition from 
controlled to compulsive alcohol use. Moreover, these neuroadaptations in the brain circuitry 
will also promote future alcohol consumption [50, 51]. 
Alcohol use is driven by both positive and negative reinforcement, however their relative 
contributions may change during the progression of AUD [52]. Positive reinforcement 
describes a situation in which a rewarding stimulus or experience (e.g., alcohol-induced 
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euphoria) increases the probability (and motivation for) for a response (e.g., alcohol-seeking 
behavior). Negative reinforcement refers to a process in which removal of an aversive 
stimulus or experience (e.g. removal of a negative emotional state) increases the probability 
of a response (e.g. relapse to alcohol drinking). Moreover, conditioned reinforcement is also 
implicated in the development and maintenance of AUD. In conditioned positive and 
negative reinforcement, stimuli that become associated with either alcohol or withdrawal 
might motivate subsequent alcohol-seeking behavior. The positive reinforcement of alcohol 
is suggested to play an important role in the beginning of alcohol use and abuse, whereas the 
negative reinforcing effects of alcohol become more critical for the motivation to drink 
alcohol during the transition to AUD [52, 53].   
Alcohol use disorder, like addiction, has been conceptualized as a progression from impulsive 
to compulsive alcohol taking in a repetitive three-stage cycle: 1) binge/intoxication, 2) 
withdrawal/negative affect, and 3) preoccupation/anticipation, that feeds in to each other, 
become more intense and worsen over time (Fig. 1) [49]. These three stages of the cycle are 
associated with specific neurochemical and neurocircuitry changes that together lead to the 
loss of behavioral control over drug seeking and drug taking. Neuroadaptive changes in the 
brain reward, stress and executive function system are suggested to play a key role in the 
development of and the transition to AUD [50, 53]. 
Initially, in the binge/intoxication stage, alcohol use is primarily motivated by positive 
reinforcement [52]. The mesolimbic DA system plays an important role in mediating the 
positive reinforcing effect of alcohol [54]. Following repeated binge/intoxication of alcohol a 
downregulation of positive reward pathways occurs, leading to that an increased levels of 
alcohol is needed to trigger the brain reward system (tolerance development) [55]. Thus, 
tolerance to alcohol’s positive reinforcing properties is an indication that the brain has started 
to change/adapt in response to repeated alcohol exposure. 
During the binge/intoxication stage, environmental stimuli such as social context and places 
become associated with the pleasurable effects of alcohol [50]. This repeated association 
might trigger an associative learning process that causes the previously neutral stimuli to 
become a reinforcer in its own right (i.e. conditioned reinforcement). Conditioned 
reinforcement as a construct is proposed to precede and set the scene for incentive salience 
[50]. Incentive salience is mediated by the mesocorticolimbic DA system and defined “as a 
psychological process that transforms the perception of stimuli, imbuing them with salience, 
making them attractive, wanted, incentive stimuli” [56]. As a result of this, the “liking” (e.g. 
pleasure value) of alcohol becomes linked to “wanting” (i.e. desire or craving) the alcohol-
associated stimuli. Following repeated alcohol exposure, this wanting might become 
pathologically amplified and provoke a strong desire or craving for alcohol which in turn 
might lead to resumption of addictive behaviors [55, 56]. Learned responses to conditioned 
drug-related stimuli might also elicit automatic responses, leading to drug-seeking and 
relapse in the absent of distinct craving [57]. Thus, both conditioned reinforcement and 
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incentive saline are suggested be implicated in cue-induced drug seeking, self-administration 
behavior and possibly also the transition to habit-like compulsive alcohol seeking [50]. 
In the withdrawal/negative affect stage, discontinued alcohol use produces a constellation of 
withdrawal symptoms. Withdrawal occurs in absence of alcohol and is characterized as a 
great discomfort for individuals with AUD [14]. Alcohol withdrawal symptoms could be both 
physical (e.g. convulsion, motor abnormalities, autonomic disturbances (e.g. sweating, higher 
heart rate)) and psychological (i.e. emergence of a negative-affective state characterized by 
anxiety, dysphoria, irritability) [15, 16]. Physiological aspects of withdrawal usually last up to 
48 hours following termination of alcohol exposure, whereas the negative affecting state are 
more long lasting and may persist into protracted abstinence. This negative emotional state is 
proposed to be a major driving force in the maintenance of AUD [14]. Thus, during the 
withdrawal/negative affect stage, alcohol drinking is primarily motivated by the desire to 
avoid this negative emotional state (i.e., by negative reinforcement) [52, 58]. The transition 
from positively to negatively reinforced drug use, possibly induced by decreased function in 
reward system and recruitment of anti-reward systems, is sometimes referred to as the “the 
dark side of addiction” [59]. 
During the withdrawal/negative affect stage of the cycle, the dopamine (DA) component of 
the reward system (within-system neuroadaptions) is compromised and brain stress 
neurotransmitters (between-system neuroadaptations) such as corticotropin-releasing factor 
and dynorphin, in the neurocircuitry of the extended amygdala, are recruited [51]. These are 
example of counter-adaptations made by the central nervous system in an attempt to 
neutralize alcohol’s effects. However, in the absent of alcohol, these opposing effects persist 
and form an ”allostatic state”. The allostatic state represents a new pathological reward set 
point outside the normal homostatic range [52]. These neuroadaptations are suggested to 
produce the withdrawal response [50, 51, 60].  
A main problem in AUD is high rates of relapse, in which addicted individuals return to 
compulsive alcohol drinking long after acute withdrawal. Relapse correspond to the 
preoccupation/anticipation stage, which is characterized by exaggerated craving for alcohol 
use [53]. Conditioned reinforcement is suggested to contribute to the 
preoccupation/anticipation stage (“craving”) stage [52]. The dysregulations that comprise the 
“dark side of addiction” are suggested to persist during protracted abstinence to set the tone 
for vulnerability to craving [59]. Craving might be driven by both environmental cues 
associated with alcohol availability and by internal states often linked to negative emotional 
states and stress. Conditioned craving is thought to have the ability to induce relapse to 
alcohol seeking and intake even after long periods of abstinence. During the 
preoccupation/anticipation stage, contextual cues via the hippocampus and stimuli cues via 
the basolateral amygdala converge with frontal cortex activity to drive drug seeking. In 
addition, other components in the frontal cortex are weakened, producing deficits in 
executive function [51]. Deficits in executive function might lead to impaired decision 
making and behavioral inhibition, which might further contribute to craving and relapse. 
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However, the reward deficits and the stress surfeit, carried over from the withdrawal stage, 
are hypothesized to be the primary driving force for relapse [61]. 
 
Fig. 1. Transition from alcohol use to AUD. A schematic picture of the addiction cycle. Initially alcohol is 
consumed for its positive reinforcing effects, driven by reward craving. However, over time, as the addictive 
process progresses a shift occurs. Alcohol use becomes compulsive and maintained by negative reinforcing 
effects (i.e. relief from a negative emotional state). Picture modified from [58]. 
Although, much of the early research focused on the acute rewarding effects of alcohol, the 
focus has been shifting towards identifying long-term neuroadaptive changes that may 
underlie relapse and excessive consumption of alcohol after periods of abstinence. The 
mesolimbic DA system is hypothesized to be implicated in the development of both positive 
and negative reinforcing effects of alcohol, and thereby contribute to the development and 
maintenance of AUD. Thus, the mesolimbic DA system represent one possibly target for 
medication development for AUD.  
1.3 DOPAMINE 
1.3.1 Brief History 
In the late 1950s, Carlsson and colleagues discovered that DA was a neurotransmitter in its 
own right and not just a precursor of norepinephrine [62, 63]. Later, Carlsson and colleagues 
proposed that DA depletion in the striatum could be the cause of neurological symptoms in 
Parkinson’s disease [64]. Today, we know that DA, in addition to motor control, is involved 
in the regulation of several important functions, such as cognition, emotions, motivation, 
reward, attention and endocrine activity. Furthermore, a dysregulation or dysfunction of the 
dopaminergic circuits has been implicated in several other brain disorders, including for 
example AUD, substance use disorder, schizophrenia, attention deficit hyperactivity disorder 
(ADHD) and Huntington’s disease [65]. 
1.3.2 Dopamine Receptors 
There are currently five known DA receptor subtypes, termed D1-D5. These receptors are 
divided into two families, the “D1-like family” and the “D2-like family”, depending on their 
structural, pharmacological and signaling properties [66]. The D1 and D5 receptors are 
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included in the D1-like family, whereas the D2-like family consists of the D2, D3 and D4 
receptors. All of these receptors are G-protein coupled transmembrane receptors [66]. 
Generally, the D1 and D2 -like receptors exerts opposite effects by activation of different 
second messenger pathways [67, 68]. Pharmacological agents could typically distinguish 
between the two families, but possess usually less specificity within each family [66]. 
All DA receptors are localized postsynaptically, whereas the D2 and D3 receptor subtypes are 
expressed both pre- and postsynaptically [69]. In the seventies, it was discovered that the 
receptor-mediated feedback mechanism adjusting the activity of dopaminergic neurons is, at 
least partly, mediated by receptors located on the dopaminergic neurons themselves. Later, 
these receptors were shown to be almost exclusively of D2 subtype and stimulation of these 
receptors result in inhibition of dopaminergic neuron with respect to firing rate, synthesis, 
release and metabolism of DA. These D2 receptors are often referred to as autoreceptors and 
are largely located extrasynaptically [70]. Generally, activation of D2 autoreceptors result in 
decreased locomotor activity, whereas activation of postsynaptic D2 receptors result in 
stimulation of locomotor activity [69]. Dopamine autoreceptors are suggested to be 
approximately tenfold more sensitive to DA and DA agonists than postsynaptic receptors, 
[71], possibly due to the fact that autoreceptors, compared to postsynaptic receptors, are 
exposed to much lower DA concentrations. 
DA receptors are expressed in regions that receive dopaminergic innervations with the D1 
receptor subtype displaying highest expression levels and being the most widely distributed 
receptor subtype [66]. In subcortical areas, the D1 and D2 receptor subtypes have roughly the 
same expression, however, in the cortex, the D1 subtype has a higher level of expression than 
D2 [66].  
1.3.3 Dopamine Pathways 
The dopaminergic system in the central nervous system can be divided into four distinct 
pathways: the nigrostriatal, the mesolimbic, the mesocortical, and the tuberoinfundibular 
pathway [72-74]. The nigrostriatal DA pathway originates in the substantia nigra and project 
predominantly to the dorsal striatum. The nigrostriatal pathway is involved in motor control. 
Symptoms of Parkinson’s disease (e.g. inhibition of voluntary movements, muscular rigidity 
and tremor) is caused by degeneration of DA neurons in this system [75]. Moreover, 
extrapyramidal side effects such as parkinsonism, dystonia, akathisia, and tardive dyskinesia 
are believed to be caused by massive blockade of D2 receptors (antipsychotic drugs) in the 
dorsal striatum [76]. The tuberoinfundibular pathway originates in the arcuate nucleus of the 
hypothalamus and projects to the pituitary stalk and is important in the inhibitory control of 
prolactin synthesis and secretion [77]. The prolactin regulation is mediated by the D2 
receptor. Thus, a common side effect from blockade of D2 receptors are increased secretion 
of prolactin (i.e. hyperprolactemia). Both the mesolimbic and mesocortical pathways have 
their cell bodies in the ventral tegmental area (VTA) and these two pathways are sometime 
referred to as the mesocorticolimbic pathway [72]. The mesolimbic pathway comprises DA 
neurons that project from VTA via the medial forebrain bundle to limbic structures such as 
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ventral striatum (i.e. the nucleus accumbens (NAc)), hippocampus, and amygdala, whereas 
the mesocortical pathway projects to cortical regions (e.g. to the prefrontal cortex (PFC)). The 
mesolimbic and mesocortical systems are involved in regulation of emotional control, 
motivation, attention, reward, cognition and the reinforcing properties of most drugs of abuse. 
The mesocorticolimbic pathway is also known to be the common denominator of the brain 
reward systems, in which the dopaminergic neurons projecting from the VTA to the NAc are 
suggested to play a central role [78-80]. 
1.4 ALCOHOL AND DOPAMINE 
Almost all drugs of abuse, including alcohol, activate the mesolimbic DA system, resulting in 
an increased DA release in the NAc [81]. However, the molecular mechanisms by which 
alcohol activates the mesolimbic DA system is still under debate. Alcohol does not interact 
with a specific receptor, instead alcohol interferes with several neurotransmitter systems in 
the brain reward and stress circuits. However, in this thesis the focus is on alcohol’s acute and 
chronic effects on the mesolimbic DA system. 
1.4.1 Brief History 
In the 1950s Olds and Milner discovered that rats implanted with brain electrodes would 
work to self-administer electrical currents into some, but not all, brain areas [82]. In specific 
brain areas, electrical stimulation were found to be highly rewarding, leading to that rats 
preferred stimulation over food (even when they were hungry) and water (even when they 
were thirsty). Later, these brain structures were anatomically mapped in more detail and 
referred to as “the brain reward system”. Normally, the brain reward circuitry leads to 
pleasurable effect through natural reinforces, such as food, water and sexual contact. When 
the brain is activated by drugs of abuse, the response is more powerful, for alcohol, as much 
as 3 to 5 times stronger, than activation triggered by natural reinforces [81, 83]. Because 
drugs of abuse are more powerful, they are hypothesized to hijack the reward systems [80], 
which might lead to the loss of interest for natural rewards often seen in AUD individuals. 
1.4.2 Acute Effects of Alcohol 
The mesolimbic DA system, which originates in the VTA and project to limbic regions such 
as the NAc, is a central component of the brain reward system [78-80, 84]. Dopamine is the 
neurotransmitter primarily involved in the mesolimbic system. Activation of this system has 
been suggested to be a key element in mediating the reinforcing and rewarding effects of 
alcohol [54]. This has been demonstrated by a numerous animal- and clinical studies [57, 78]. 
For example, like most drugs of abuse, systemic administration of alcohol elevates 
extracellular DA concentrations in the NAc [81, 85, 86]. Similarly, alcohol self-
administration produces a dose-dependent rise in DA levels in the NAc in rats [87]. 
Moreover, previous studies have shown that alcohol increases the firing rate of VTA DA 
neurons in rats [88, 89]. In addition, in a human study, intoxicating doses of alcohol increased 
extracellular DA in the ventral striatum (including NAc) [90] and increased extracellular DA 
in the striatum has been shown to correlate with self-reported “high” in healthy controls [91]. 
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Collectively, these studies indicate that activation of the mesolimbic DA system most likely 
play an important role for the positive reinforcing effects of alcohol. Supportively, reduced 
alcohol-reinforced responding have been demonstrated following microinjections, into the 
NAc or VTA, of pharmacological agents that interfere with DA transmission [92, 93]. 
Additionally, mice deficient in DA D1 or D2 receptors show attenuated operant self-
administration of alcohol [94], alcohol intake and preference [95], as well as conditioned 
place preference for alcohol  (CPP) [96]. However, in spite of extensive evidence, several 
early studies have challenged the involvement of accumbal DA in alcohol reinforcement by 
showing that lesions of the mesolimbic DA system do not completely abolish alcohol-
reinforced behavior [97, 98]. These studies might indicate that DA is an important, but maybe 
not essential, component of alcohol reinforcement. 
In addition to alcohol reward, activation of the mesocorticolimbic DA system has been 
hypothesized to play a key role in incentive salience. Specifically, the function of midbrain 
DA neurons might be to direct behavior toward salient rewarding stimuli [56].  Weiss and 
colleagues have demonstrated that even the anticipation of alcohol availability have the 
potential to increase DA levels in the NAc in rats conditioned to 10% alcohol [87]. 
Furthermore, in another study, Philpot and Kristein demonstrated that following repeated 
injections of alcohol, saline injections alone evoked DA increase in the NAc [99]. In addition, 
in abstinent alcohol dependent individuals, alcohol-associated stimuli activated the ventral 
striatum [100]. Together, these studies indicate that the mesocorticolimbic system might play 
a role for the initiation of alcohol seeking, which in turn might contribute to alcohol craving 
and relapse. Supportively, the DA receptor antagonist haloperidol have been shown to reverse 
conditioned reinforcing effects of a discrete stimulus previously paired with alcohol [101] 
and reinstatement of responding for alcohol induced by a discriminative stimulus was 
blocked by either DA D1 or D2 receptor antagonists [102]. Moreover, Hamlin and colleagues 
showed that systemic injections of the DA D1 receptor antagonist SCH 23390 blocked 
context-induced reinstatement [103] and Chaudhri and colleagues found that SCH 23390 
injections into either NAc shell or core attenuate this reinstatement [104]. 
A multitude of other neurotransmitters might contribute to the positive reinforcing properties 
of alcohol by direct or indirectly activation of the brain reward circuitry [55]. For instance, 
alcohol has been proposed to increases the release of endogenous opioid in the VTA, 
resulting in an inhibition of GABA-ergic interneurons. Normally, these GABA-ergic 
interneurons exert a tonic inhibition of dopaminergic VTA neurons. Therefore, an inhibition 
of the GABA-ergic interneurons will result in disinhibition of the dopaminergic neurons, 
which subsequently will release DA in NAc [54, 79, 105]. The subsequent release of DA in 
NAc is believed to contribute to the rewarding effects of alcohol, as well as opiates [54, 79, 
106]. However, alcohol intake is also suggested to result in endogenous opioid release in 
terminal areas of mesolimbic and mesocortical projections [107]. Importantly, several other 
neurotransmitters, for example, GABA, glutamate, acetylcholine, serotonin, as well as 
hormones (e.g. ghrelin) have been suggested to play important roles for alcohol reward and 
intake [78].   
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1.4.3 Chronic Effetcs of Alcohol 
Following chronic alcohol exposure, a dysregulated DA activity has been demonstrated, 
hypothesized to reflect adaptations in mesolimbic DA function to counter sustained 
stimulation by alcohol. In contrast to alcohol’s acute effects on mesolimbic DA 
neurotransmission, withdrawal from chronic alcohol use is associated with mesolimbic DA 
hypofunction. This is supported by animal studies showing that chronic alcohol use induced a 
substantial reduction in extracellular NAc DA levels [108], downregulation of D2-receptors 
[109], and a decreased activity in VTA DA neuron [110]. Additionally, human imaging 
studies have shown decreased DA release [111], paralleled by a reduction in DA D2 receptors 
[112] in detoxified alcohol dependent individuals. Moreover, following 3 weeks of alcohol 
drinking, changes in NAc DA turnover and synthesis was shown 2 months after alcohol 
withdrawal in mice [113], indicating that decreased DA release might be a long-lasting 
phenomenon. Thus, the persistence of DA deficient during protracted abstinence might have 
implications for vulnerability to relapse [114], as well as the adverse symptoms associated 
with protracted alcohol withdrawal. Interestingly, in a clinical study, a slow rate of recovery 
of DA receptor function predicted relapse and poor treatment outcome in alcohol dependent 
individuals [115]. In summary, this hypofunction of the mesolimbic DA system following 
chronic alcohol exposure is suggested to play an important role in the maintenance of AUD 
by motivating resumption of alcohol drinking during withdrawal to reverse DA deficits. 
Supportively to this hypothesis is a study showing that rats undergoing alcohol withdrawal 
will self-administer just enough alcohol to return DA levels to normal [116]. 
The transition from controlled alcohol use to AUD not only involve a compromised brain 
reward system, but also the recruitment of the brain stress systems such as the corticotropin-
releasing factor, norepinephrine and dynorphin in the extended amygdala [14, 55]. These 
dysregulations in the stress systems are producing aversive or stress-like states and are 
suggested to contribute to the negative emotional states in withdrawal and protracted 
abstinence [61]. Thus, the combination of decreased reward system function and recruitment 
of brain stress systems provides a powerful motivation for relapse during both acute and 
protracted abstinence. A compound with DA stabilizing properties might have potential to 
counteract both positive and the negative reinforcing effects of alcohol, and thereby provide 
one potential drug candidate.  
Following chronic alcohol use, components in the PFC might be compromised, resulting in 
deficits in executive function [51]. Generally, the function of the PFC is to engage executive 
function and disruption in this system might lead to impaired decision making and behavioral 
inhibition. Deficits in executive function, particularly in the preoccupation/anticipation, are 
often seen in AUD individuals [117, 118], which might increase the vulnerability to relapse. 
In fact, clinical studies have found detoxified AUD individuals to demonstrate poor inhibitory 
control in several behavior tasks, such as stop signal serial reaction [119], continuous 
performance task [120] and Go/No-Go task [121]. In addition to be involved in AUD, the DA 
system and D2 receptors are suggested to be involved in the complex regulation of impulsive 
behavior [122]. Indeed, long-term alcohol vapor exposure, profoundly disrupted D2/D4 
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modulation of PFC neural activity in rats medial PFC [123]. Moreover, a decreased DA 
transmission in PFC [124] and an association between a reduction in striatal D2/D3 receptors 
and a decreased metabolic activity in prefrontal regions necessary for executive control (e.g. 
inhibitory control) [125] have been observed in AUD individuals. In addition, low striatal DA 
D2 receptor availability have in turn been linked to increased impulsivity in rodents [126], as 
well as in social drinkers and individuals with AUD [127], Thus, enhancement of cognitive 
functions (e.g. improve impulse control), possibly through modulation of DA transmission, 
might provide an additional approach to prevent relapse.  
1.5 DOPAMINE AS A POTENTIAL THERAPEUTIC TARGET FOR AUD  
Given the involvement of DA in the development and maintenance of AUD, the DA system 
has previously been evaluated as a potential treatment target for AUD [128]. Activation of the 
mesolimbic DA pathway is believed to contributing to the acute reinforcing properties of 
alcohol [129] and traditional DA receptor antagonists (neuroleptics) reduce alcohol craving 
and alcohol reinforcement [128]. However, the use of DA antagonists are limited by severe 
side effects (including extrapyramidal effects) resulting from excessive DA inhibition. In 
addition, the DA antagonist flupenthixol induced relapse in recently detoxified AUD patients 
[130]. Dopamine agonists have also been evaluated as potential therapeutics based on the 
hypothesis that chronic alcohol consumption might create a dysphoric state as a result of 
decreased DA release [111], paralleled by a reduction in D2 receptors [112]. Although 
medications that increase DA activity might theoretical have potential in the treatment of 
AUD, reported results have been conflicted [128]. For example, the DA D2 agonist 
bromocriptine, was suggested to reduced drinking in alcohol dependent individuals [131], but 
a subsequent, randomized, double-blind, placebo-controlled study failed to show any 
difference in relapse between bromocriptine and placebo [132]. Recently, the partial D2-
agonist, aripiprazole was shown to decrease alcohol consumption in alcohol preferring AA-
rats [133], as well as alcohol intake in AUD patients [134-136]. However, in a 12-week, 
double-blind, placebo-controlled treatment study with 295 AUD individuals, Anton and 
colleagues did not find any effect of aripiprazole in heavy drinking days compared to placebo 
[137]. Nevertheless, these results indicate that normalization, rather than antagonism or 
agonism, of the DA system might be a promising strategy for AUD treatment. Interestingly, 
aripiprazole has been shown to have DA stabilizing properties, which also has been 
demonstrated for (-)-OSU6162 (OSU6162) [70], the compound evaluated in this thesis. 
However, it should be noted that aripiprazole’s and OSU6162’s mechanism of action are not 
the same. 
1.6 THE MONOAMINE STABILIZER (-)-OSU6162 
1.6.1 Brief History 
The monoamine stabilizer (-)-OSU6162 (OSU6162) [138] belongs to a pharmacological class 
of compounds originally named “dopamine stabilizers” based on the ability of these 
compounds to act normalizing on dopaminergic signaling depending upon the prevailing 
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dopaminergic tone [70]. Dopamine has an essential role in the expression of spontaneous and 
stimulant-induced activity [139]. Therefore, locomotor activity has been used as a behavioral 
model to describe DA stabilizers. The first DA stabilizers were synthesized by Dr. Arvid 
Carlsson and colleagues as part of a project aiming at developing a novel treatment for 
schizophrenia with better pharmacokinetic properties and less severe side effects [70].This 
project lead to the discovery of compounds with intriguing effects on the DA system; One of 
them being the partial D2 agonist, (-)-3-PPP [140]. A partial D2 agonist will bind to DA 
receptors located both pre- and postsynaptic and produce agonist activities, but lower than 
that of DA. The level of receptor activation will correspond to the intrinsic activity of the 
partial D2 agonist. (-)-3-PPP has undergone trials in schizophrenic patients [141, 142] and 
was found to possess antipsychotic activity without inducing any serious side effects. 
However, the antipsychotic action was not sustained for more than 1 week, possibly due to 
desensitization of the receptor by the agonist [141]. Thus, it was suggested that a partial D2 
receptor with lower intrinsic activities may possess a more long-lasting antipsychotic activity. 
The partial D2 agonist, aripiprazole, a further development of (-)-3-PPP [143], is one such 
compound and has been approved by the FDA for the treatment of schizophrenia [144, 145]. 
Thereby, aripiprazole, was the first claimed “dopamine stabilizer” to be commercially 
available. 
OSU6162 is a further development from (-)-3-PPP and has the ability to stimulate, inhibit, or 
show no effect on DA-related behaviors depending upon the prevailing dopaminergic tone 
[138, 146, 147]. For example, OSU6162’s ability to suppress DA activity is illustrated by 
inhibition of amphetamine-induced hyperlocomotor activity in rats [146] and sub-human 
primates [148]. In contrast, stimulation of DA activity is shown through increased locomotor 
activity in rats habituated to their environment [138, 146, 147]. Importantly, these buffering 
effects on DA transmission were observed without the presence of motor impairments or 
catalepsy [138, 146]. The normalizing and stabilizing profile of OSU6162 is further 
supported by a previous positron emission tomography study in anaesthetized rhesus 
monkeys, showing a reduction in the striatal L-[11C]DOPA influx rate in monkeys with high 
baseline values and an increased striatal L-[11C]DOPA influx rate in monkeys with low 
baseline values [149]. Together, these studies indicate that OSU6162’s DA stabilizing 
properties appears to depend on the current baseline in DA activity. 
1.6.2 OSU6162’s Mechanism of Action 
The exact mechanisms behind OSU6162’s ability to modify DA-related behaviors in a 
bidirectional manner are not fully understood. Although, OSU6162, like (-)-3-PPP and 
aripiprazole, has been shown to display partial agonist effects in vitro [150, 151], and is 
considered a “dopamine stabilizer”, the observed effects of OSU6162 cannot be explained by 
partial D2 receptor agonism [70]. In fact, OSU6162 have failed to demonstrate any intrinsic 
activity in vivo [138, 146]. In a behavior study, evaluating the effects of OSU6162, (-)-3-PPP 
and aripiprazole on locomotor activity, all three compounds caused inhibition of locomotor 
activity in rats introduced to a novel stimulating environment (highly active rats). However, 
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only OSU6162 was able to induce any activation in rats habituated to their environment 
(inactive rats) [147].  However, following reserpine-induced DA-depletion (i.e. in the absence 
of DA) a minor stimulation of locomotor activity was observed in rats treated with (-)-3-PPP 
[140], an effect indicating D2 receptor stimulation. In contrast, OSU6162 did not induce any 
behavioral activation in rats treated with reserpine [138], and failed to induce rotational 
behavior in 6-hydroxy-DA-lesioned rats [152], suggesting lack of D2 agonist-like effects. 
Instead, these studies indicate that the behavioral activating effects of OSU6162 is due to an 
indirect effect mediated by DA.  
Based on early in vitro studies, OSU6162 was suggested to be a D2/D3 receptor antagonist 
with very low affinity, and with no detectable affinity for a selection of other receptor types 
[138]. Indeed, the ability of OSU6162 to blunt amphetamine-induced hyperactivity was lost 
in DA D2 knockout mice [153], giving support for the involvement of D2 receptor blockade in 
the behavioral effects of OSU6162. 
In two different studies, OSU612 was shown to induced dose-dependent increase in prolactin 
levels [146, 154], an effect associated with D2 receptor blockade. In addition, functional 
experiments have reported that OSU6162, like traditional D2 antagonists, elevate DA 
synthesis, DA release, and DA metabolism in untreated rats [138]. However, animal behavior 
experiments have demonstrated a clear distinction between OSU6162 and traditional D2 
receptor antagonists [70]. For example, OSU6162 (3-60 mg/kg), over a D2 occupancy range 
of 37 to 87%, showed a tone-dependent mixture of stimulatory and depressant effects on 
locomotor activity in rats without inducing any catalepsy [146]. In contrast, in the same 
study, over a similar occupancy range, haloperidol (a traditional D2 antagonist) inhibited 
psychostimulant activity but induced catalepsy and failed to activate rats habituated to their 
environment [146]. 
There is no obvious mechanism by which OSU6162 could stabilize dopaminergic 
transmission. However, a proposed mechanism of OSU6162 is a relative preference for 
extrasynaptic versus synaptic D2 receptors [70]. This hypothesis postulates that, in case of 
low to normal dopaminergic tone, OSU6162 may stimulate dopaminergic signaling by 
blockade of D2 autoreceptors. Instead, in case of an elevated dopaminergic tone, OSU6162 
may dampen transmission mediated by extrasynaptic D2 heteroreceptors [70]. Another 
suggested mechanism is that OSU6162 might have a dual action on D2 receptors by 
interaction with both an allosteric and an orthosteric site on the receptor in order to stimulate 
or inhibit dopaminergic neurotransmission [150]. When the DA level is low, OSU6162 acts 
on the allosteric site on D2 receptors causing an enhanced effect of DA, presumably due to a 
conformation change. This change might in turn lead to an increased activation of the D2 
receptor or an increased affinity to DA [150]. On the other hand, if DA levels are high, 
OSU6162 will bind to the orthosteric site and antagonize the receptor, causing DA inhibition 
[150]. However, additionally, mutually counterbalancing effects, involving both agonism and 
antagonism in different receptor location or sites, probably exist. Indeed, recently, OSU6162 
was shown to have stabilizing properties on the serotonergic neural circuits, acting as a partial 
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agonist, notably on the 5-HT2A receptors [155]. Thus, the wider classification “monoamine 
stabilizer” is a more appropriate name for this class of compounds. 
1.6.3 Clinical Applications of OSU6162 
OSU6162, with its unique ability to stabilize DA transmission, might constitute a potential 
treatment for a variety of conditions involving dysregulation or dysfunction in the 
dopaminergic circuits of the brain. Indeed, OSU6162 has been tested as potential therapeutics 
for Huntington’s disease [156, 157], schizophrenia [158, 159], and more recently for mental 
fatigue following stoke or traumatic brain injury [160]. All these clinical studies have 
demonstrated that OSU6162 appears to be clinically safe with side effects of mild severity. 
Thus, a great advantage of OSU6162 compared to traditional D2 antagonists, might be the 
lack of extrapyramidal reactions [161]. Moreover, stabilizing of dopaminergic transmission 
would be particularly useful in the treatment of conditions involving both increased and 
decreased DA signaling, as suggested in the case of AUD. OSU6162’s potential to target the 
DA system in brain regions relevant for AUD is supported by a recent human PET study 
showing that OSU6162 preferentially binds to D2/D3-receptors in the striatum [162]. In 
addition, Natesan and colleagues, demonstrated that OSU6162 induced expression of Fos, a 
marker of neuronal activity [163], preferentially in NAc compare to dorsolateral striatum in 
rats [146]. 
1.7 ANIMAL MODELS OF AUD - FOCUS ON VOLUNTARY ALCOHOL INTAKE 
Animal models are important in promoting knowledge of neurobiological mechanisms and 
neurocircuitries involved in drug-seeking behavior and new potential targets for medication 
development [164]. In addition, in animal experiments, experimental conditions can be 
controlled and therefore give essential insight into casual relationships that would be 
impossible, or unethical, to do in humans. Rats are a common and suitable species for 
determining the biological basis of drug self-administration and relapse because their reward 
pathways display a high degree of similarity to humans [165]. Alcohol use disorder is a 
complex disorder with a major heterogenecity, where genetic predisposition, age of onset, 
incidence of withdrawal, environment factors and pattern of drinking differs a lot between 
AUD individuals [166]. Thus, no single animal model can capture the complexity of or 
manifest all symptoms of AUD. Instead, different animal models are used to reflect various 
aspect of AUD, such as excessive alcohol drinking, increased motivation to take alcohol, and 
relapse to alcohol seeking [167]. When developing and utilizing animal models, the model’s 
face, construct, and predictive validity are important to consider. The face validity refers to 
the similarity in symptoms between the animal and the human condition. The construct 
validity refers to whether there is a similarity in the mechanisms underlying the behavior in 
the model and the behavior in the human condition. The predictive validity refers to whether 
the results obtained predict the response in human, such as a treatment response [168].  
The studies in this thesis combine a battery of different animal models, used to model 
different aspects of AUD, to evaluate the potential of OSU6162 as a novel treatment for 
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AUD. Moreover, we use outbred (standard) laboratory rats and focus on voluntary alcohol 
intake models to, in the best way, represent the heterogeneous human population and 
resemble human alcohol consumption, respectively. Therefore, forced alcohol intake models 
will not be described here. 
1.7.1 Alcohol Intake Models 
In humans, alcohol is taken voluntarily and ingested orally. Thus, voluntary alcohol 
consumption becomes an important aspect in animal models of alcohol intake. Operant self-
administration models and home-cage alcohol drinking models are both voluntary alcohol 
intake models [167]. Voluntary alcohol intake models can from a behavioral perspective be 
classified as operant and non-operant procedures, which are distinguished from each other on 
the basis of the behavior required to obtain alcohol. In home-cage alcohol drinking models, 
i.e. non-operant models, rats are presented with an alcohol bottle in the home-cage, whereas 
in the operant self-administration models, rats are required to produce an operant response 
(e.g. press a lever) to get access to alcohol [167].   
Historically, it has been a challenge to obtain high alcohol consumption in standard 
laboratory rats because rats do not generally prefer alcohol over water. Consequently, several 
different initiation procedures have been developed in order to increase the alcohol 
consumption, such as water/food deprivation [169] or taste masking with sucrose fading 
procedures [170]. Despite these efforts, rats rarely maintain high alcohol consumption when 
the initiation procedures are removed. In addition, results from models using food or fluid 
deprivation might be difficult to interpret because alcohol consumption could be motivated 
by thirst or the need for the calories, and not by the pharmacological effects of alcohol. 
Another attempt to increase alcohol consumption in rats is the use of rat strains selectively 
bred for high preference for alcohol [171, 172]. However, in drug development, interpretation 
of data using genetically modified animals might be difficult, as inbred rats are not easily 
translated into the general human population. Nevertheless, selectively bred rat lines might be 
a good model to evaluate genetic components underlying susceptibility or resistance to AUD. 
1.7.1.1 Intermittent Access 20% Ethanol Model 
The Intermittent Access 20% Ethanol (IA20E) model was first introduced in the early 1970s 
and showed that standard laboratory rats voluntary consume high levels of alcohol without 
any initiation procedure, if an intermittent schedule to 20% alcohol in a 2-bottle-choice 
paradigm was applied [173]. This early study showed that repeated cycles of free-choice 
alcohol intake led to considerably higher alcohol intake compared to rats given continuous 
access to alcohol [173]. More recently, the model was revived [174] and have since then gain 
popularity in the alcohol field [175].  
In the IA20E model, rats get access to alcohol in the home-cage during specific days of the 
week (typically Monday, Wednesday, and Friday). Water is available ad libitum. At early 
stages of this procedure, rats consume relatively low levels of alcohol but will gradually 
escalate over time [173, 174] reaching an alcohol intake between 3-6 g/kg/day [175]. This 
 18 
drinking pattern might model the transition from social-like drinking to excessive alcohol 
drinking in humans. Although, this model has several important advantages, a limitation with 
this model might be that a variability in alcohol intake exists and all rats due not escalate or 
drink excessive amounts of alcohol [175]. However, this individual variability in alcohol 
intake could also be seen as an advantage of the model, because in a way this represents the 
heterogeneous human population.  
Previous studies have suggested that the IA20E model in addition to study initiation, and 
maintenance of excessive alcohol intake, also might be used to study binge-like alcohol 
drinking [175]. In fact, Carnicella and colleagues showed that the IA20E model induced 
pharmacologically relevant blood ethanol concentrations (BECs) reaching a mean BEC value 
of > 80 mg% [176], which meets the criteria of the National Institute on Alcohol Abuse and 
Alcoholism (NIAAA) for binge drinking in humans (National Institute on Alcohol Abuse and 
Alcoholism, 2004). Although rats reach high levels of alcohol consumption in the IA20E, the 
method might not be sufficient to induce alcohol dependence. Models that are suggested to 
induce alcohol dependence in rats are using forced alcohol exposure, e.g. the alcohol vapor 
model [177]. However, an obvious limitations using alcohol vapor procedures are the lack of 
face validity. In addition, this excessive, experimenter-imposed alcohol exposure might act as 
a non-specific stressor in the rats, which might lead to confounding results. 
1.7.1.2 Operant Self-Administration Model 
Alcohol’s positive and negative motivational effects are believed to be important factors in 
motivating drinkers to increase or decrease their alcohol intake [178]. Therefore, a variety of 
animal behavioral models aim to measure alcohol’s motivational effects have been 
developed. One such model is the operant self-administration model, which is based on 
procedures originally developed by B.F. Skinner in 1938 using food as reward [179].  
The operant self-administration model is a commonly used model in which animals are 
trained to self-administer alcohol typically by pressing a lever in operant conditioning 
chambers [180]. The operant chamber is usually equipped with two levers defined as active 
and inactive. The active lever is linked to the alcohol delivery, whereas the inactive lever is 
linked to vehicle or has no programmed consequence. The inactive lever is used as a measure 
of nonspecific behavioral activity. The self-administration model is used to explore the 
motivational aspects of alcohol seeking (craving) in rodents [178]. Using this model, different 
schedules of alcohol reinforcement can be applied, which will determine how hard the animal 
will have to work to obtain one alcohol delivery. Operant training is typically performed on a 
fixed-ratio (FR) 1 schedule of reinforcement, in which every operant response (e.g. lever 
press) is reinforced with the delivery of alcohol. Another commonly used schedule is the 
progressive-ratio schedule (PR) of reinforcement. In the PR schedule of reinforcement, the 
requirement for obtaining alcohol (the number of lever presses) are progressively increased 
within the session [167]. The PR schedule of reinforcement is used to determine an animal’s 
willingness to work to obtain alcohol and the point at which responding ceases is called the 
  19 
“breakpoint” [181]. The breakpoint is thought to provide an index of the reinforcing efficacy 
of the drug [182].   
1.7.1.3 Pros and Cons with Operant vs Non-Operant Models  
The IA20E model present good face validity for human alcohol consumption, because the 
alcohol is ingested orally and voluntary in repeated cycles. Moreover, in a study using in vivo 
microdialysis, a decreased DA overflow in NAc was observed following 7 weeks of drinking 
in the IA20E model [183]. Furthermore, we have demonstrated that the IA20E model might 
induce a hyperglutamatergic state in rats, typified by an increased NMDA- and AMPA-
induced currents in pyramidal cells in the medial PFC, following 3 months of high alcohol 
consumption. These two studies, showing neuroadaptations in the mesolimbic DA system 
and on glutamatergic transmission, are examples of studies that provide the IA20E model 
with construct validity. Moreover, naltrexone and acamprosate, two medications approved for 
treatment of AUD, have been demonstrated to decrease alcohol intake in this model [174, 
184]. In addition, varenicline has been shown to decrease alcohol intake in the IA20E model 
[185], as well as percent heavy drinking days and drinks per drinking day in alcohol 
dependent patients, compared with placebo, in a multicenter, double-blind, placebo-
controlled clinical trial [186]. Together these translational studies, give the IA20E model 
predictive validity and support the potential of this model as a good preclinical tool in drug 
development. 
An advantages with the use of an operant self-administration model, compared with the 
IA20E model, is that the operant self-administration model provides more flexibility in the 
experimental design which thereby could provide more information. For example, the 
temporal distribution of the responses can be analyzed [167]. On the other hand, the operant 
self-administration model requires a relatively long training period, and not all rats will 
successfully acquire operant alcohol self-administration [175]. However, once stable 
responding levels are achieved, operant self-administration is very versatile model in terms of 
behavioral assessment [167]. The operant self-administration model has had an important role 
in the preclinical validation and characterization of naltrexone [187, 188] and acamprosate 
[189, 190], indicating some predictive validity. Although, humans do not have to press a 
lever to gain access to alcohol, the operant self-administration model still present some face 
validity, because humans ingest alcohol orally and drink alcohol voluntary where they control 
the amount consumed and the pattern of consumption.  
In summary, the IA20E model focus on consummatory aspects, whereas the operant self-
administration model captures both the consummatory and the motivational aspects of 
alcohol consumption [178]. Therefore, in this thesis (Paper I), we use both the IA20E model 
and the operant self-administration model (a PR schedule of reinforcement) to evaluate 
OSU6162’s potential to decrease alcohol consumption and the motivation to seek alcohol. 
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1.7.2  Relapse-like Drinking Models 
A main problem in the treatment of AUD is the long-lasting vulnerability to relapse [191]. 
Relapse to alcohol could be modelled by the alcohol deprivation model [192] and by 
reinstatement models [193]. 
1.7.2.1 The Alcohol Deprivation Model 
The alcohol deprivation model is based on the observation of a temporary rise in alcohol 
intake following a period of forced abstinence, a so-called alcohol deprivation effect (ADE) 
[167]. The ADE was first described in rats by Sinclear and Senter [194] and has in recent 
years become a widely used paradigm in examining relapse-like drinking behavior [195]. The 
exact mechanism behind the ADE is not clear, but alcohol itself might act as a cue (i.e. taste, 
smell) or/and a priming stimuli triggering the ADE [167]. Alternatively, the ADE might by 
caused by an increased reinforcing value of alcohol [192].  
1.7.2.2 The Reinstatement Model 
The reinstatement model was introduced to the drug addiction field in the early 1970s [196] 
and has over the years become a well-established model to study drug-seeking behavior 
[193]. The reinstatement model refer to the resumption of extinguished lever-pressing 
behavior after non-contingent exposure to drug or non-drug stimuli [197]. In the 
reinstatement model, rats are trained to self-administer a drug of abuse, such as alcohol, by 
typically pressing a lever in an operant conditioning chambers. The alcohol seeking behavior 
(lever pressing) is then extinguished in the absence of alcohol. During the reinstatement test, 
reinstatement of drug seeking behavior is defined as significantly higher responding on the 
lever previously paired with drug following exposure to the experimental manipulations as 
compared with the control manipulations [197]. Re-exposure to alcohol [24, 198], exposure 
to environmental contexts [199] or alcohol cues[200] previously paired with alcohol, and 
exposure to a stressful stimuli [198] are different manipulations typically used to reinstate 
alcohol seeking in laboratory animals.  
1.7.2.3 Pros and Cons with Relapse-like Drinking Models 
The concept of ADE has been observed in individuals with AUD [201] and the model has 
therefore been suggested to have face and construct validity [167]. Regarding predictive 
validity, naltrexone and acamprosate, have shown to prevent the ADE in rats [192, 202], as 
well as craving-induced relapse in humans [44]. 
For the reinstatement model, it should be noted that in contrast to relapse in AUD individuals, 
this model measure relapse-like behavior in a drug-free state. Thus, this model might be 
better referred to as a model measuring alcohol-seeking behavior [167]. However, the 
reinstatement model is suggested to have face validity for relapse due to the fact that factors 
reported to reinstate alcohol seeking in laboratory animals (alcohol-priming, cue, and stress) 
also provoke relapse and craving in humans [201]. In addition, naltrexone and acamprosate, 
which has been shown to decreases relapse tendencies in humans, has been shown to 
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decrease alcohol-priming or cue-induced reinstatement of alcohol seeking in rats [188, 203, 
204], supporting the predictive validity of the reinstatement model.  
A limitation with both the reinstatement and the ADE model, is the use of a forced abstinence 
period (i.e. extinction training or removal of the alcohol from the cage). In AUD individuals, 
abstinence from alcohol, unless treated in an inpatient facility, is typically initiated when 
alcohol is available due to the negative consequences associated with excessive drinking 
[205, 206]. However, recently, new models have been developed in an attempt to more 
closely mimic the human condition. For example, Marchant and colleagues have developed a 
model of context-induced relapse where active alcohol-taking behavior is suppressed by 
negative consequences using a mild footshook [207].  
In summary, the ADE model appears to be suitable to study the impact of alcohol re-exposure 
on relapse, whereas the reinstatement model can address the impact of environmental factors 
and stress on alcohol seeking prior to drug use [195]. Thus, the ADE model and the 
reinstatement model might be a good complement to each other in the screening for new anti-
relapse agents. We therefore, in this thesis, used both the ADE model (Paper III) and a 
cue/priming-induced reinstatement model (Paper I) to evaluate the potential of OSU6162 to 
attenuate relapse-like behavior. In addition, we used a context-induced reinstatement model 
[208] to examine the effect of OSU6162 on oxycodone seeking induced by re-exposure to the 
drug seeking environment (Paper IV). This model have previously been used to reinstate drug 
seeking behavior for several drugs of abuse including heroin [209] and oxycodone (Bossert et 
al., unpublished data). 
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2 AIM OF THE STUDY 
The overall aim of this thesis was to evaluate the potential of OSU6162 as a novel treatment 
for AUD using validated preclinical models of behaviors related to AUD. 
 
Specific Aims:  
Paper I: To evaluate OSU6162’s potential to decrease alcohol intake, alcohol seeking, alcohol 
withdrawal symptoms, and cue/priming-induced reinstatement of alcohol seeking in long-
term alcohol drinking rats. 
Paper II: To evaluate the rewarding properties of OSU6162 in alcohol-naïve and long-term 
alcohol drinking rats using CPP. 
Paper III: To evaluate the effects of OSU6162 on relapse-like alcohol drinking and motor 
impulsivity in alcohol-naïve and long-term alcohol drinking rats. 
Paper IV: To examine the effects of OSU6162 on oxycodone self-administration and context-
induced reinstatement and thereby evaluate the potential of OSU6162 on another drug of 
abuse. 
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3 MATERIAL AND METHODS 
This section provides a brief description of the animals, the drugs, the different animal 
models, and statistics used in this thesis. Detail descriptions of the animals, drugs and 
methods could be found in the papers/manuscripts. It should be noted that the microdialysis 
experiments (Paper I: Conducted and analyzed by Björn Schilström; Paper II: Conducted and 
analyzed by Kristin Feltmann) and the novel object recognition experiment (Paper II: 
Conducted and analyzed by Kristin Feltmann) were not included in this thesis project and the 
methodological aspects will therefore not be described here. Information about these studies 
could be found in Paper I and Paper II.  
3.1 ETHICAL CONSIDERATIONS 
Despite the severe consequences of AUD, only four medications have been approved in 
Sweden for this disease. The varying and limited clinical efficacy of these pharmacotherapies 
justify the search for more effective medications to help AUD individuals reduce their 
drinking and combat their disease. Thus, this thesis provides valuable information for a 
potential novel medication for AUD which might benefit a huge patient group that today lack 
adequate treatment. 
The work presented in this thesis consist of animal experiments, all designed to minimize the 
number of animals and their suffering. The experiments in Paper I-III were carried out in 
strict accordance with the recommendations in the Swedish Animal Welfare Act and 
approved by the Swedish Ethical Committee on Animal Research in Stockholm (diary 
numbers: N427/11, N475/12, and N163/14). The experiments in Paper IV were performed in 
strict accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (8th edition), under protocols approved by the Animal Care and Use 
Committee (# 14-BNRB-25). 
3.2 ANIMALS 
Male Rcc Han Wistar rats were purchased from Harlan (Netherlands) and used in Paper II 
and III and for all behavior experiments in Paper I. In Paper IV, male Sprague Dawley rats 
were used and obtained from Charles River Laboratories (Wilmington, MA, USA). All rats 
were housed under standard laboratory conditions with controlled temperature and humidity.  
Food and water were freely available in all experiments except for the 5-Choice Serial 
Reaction Time Task (5CSRTT) experiment in Paper III and the food self-administration 
experiment in Paper IV, in which food restriction was applied (20 g/day). Rats were housed 
individually in most of the experiments (for details see papers/manuscripts). 
3.3 DRUGS 
The monoamine stabilizer (-)-OSU6162 [(S)-(-)-3-(3-methanesulfonyl-phenyl)-1-propyl-
piperi- dine] (or PNU-96391) was generously donated by Dr. Arvid Carlsson (Sahlgrenska 
Academy, University of Gothenburg) and dissolved in saline (B. Braun Malsungen AG, 
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Germany). OSU6162 was injected subcutaneously (sc), at a volume of 5 ml/kg, 30 or 60 min 
prior to the start of the test sessions. The OSU6162 doses used in this thesis were based on a 
previous study showing that this dose range induces high striatal D2 receptor occupancy 
without inducing catalepsy in rats [146]. Saline was used as vehicle.  
Alcohol drinking solutions were prepared in tap water from 95% (v/v) ethanol (Apoteket AB, 
Stockholm, Sweden) in Paper I and 96% (v/v) ethanol (Solveco AB, Sweden) in Paper II and 
III. The other drinking solutions, used in Paper I, were prepared in tap water from NaCl 
(Sigma Aldrich, Stockholm, Sweden) or sucrose (Sigma Aldrich, Stockholm, Sweden). 
Oxycodone, used for the self-administration experiments in Paper IV, was received from the 
National Institute on Drug Abuse (NIDA) pharmacy and dissolved in sterile saline. The 
oxycodone doses were based on unpublished data from Dr. Yavin Shaham’s laboratory 
(NIDA). 
3.4 ANIMAL MODELS 
3.4.1 Intermittent Access 20% Ethanol (IA20E) Model  
The IA20E method induces voluntary intake of high amounts of alcohol without the use of an 
initiation procedure [173, 174]. In the IA20E method, rats had access to 20% alcohol during 
three 24-hour drinking-sessions per week (Monday, Wednesday and Friday) and water was 
always available. On Alcohol days, each rats was given access to one bottle of 20% alcohol 
and one bottle of water. After 24 h, the alcohol bottle was replaced with a second water bottle 
for the subsequent 24 h. The following day, the second water bottle was replaced with the 20 
% alcohol bottle. The location of the alcohol bottle was alternated from the previous session 
to control for side preferences. During the weekend, rats receive free access to water. Alcohol 
intake per kilogram of body weight (g/kg), the preference for alcohol over water (the ratio of 
alcohol to total fluid intake), water intake and total fluid intake were calculated by weighing 
the rats and the bottles. Bottles were typically weighed both 4 and 24 hours after the fluids 
were presented with some exceptions where only the 24 h measurements were taken. The 
procedures for the salty- and sweet-solution experiments (Paper I) were identical with the 
IA20E model, with the exception that the alcohol solution was replaced with a bottle of 
0.175% sodium chloride (NaCl) or 5% sucrose, respectively. 
In Paper I, the effects of acute and repeated OSU6162 treatment on alcohol intake were 
evaluated. The acute OSU6162 treatment data were analyzed using a repeated measures 
analysis of variance (ANOVA) with the within-subjects factor of OSU6162 treatment (0, 15, 
and 30 mg/kg). Moreover, the repeated OSU6162 treatment data were analyzed using a 
repeated measures ANOVA with the within-subjects factors of OSU6162 dose (0 and 30 
mg/kg), and day (5 alcohol sessions during treatment and 5 drinking sessions post treatment). 
3.4.2 Modified Novel Cage Test (NCT) 
The Novel Cage Test (NCT) [210] was developed to evaluate emotional reactivity in mice by 
quantifying exploration and risk assessment behaviors. In this thesis, a modified NCT was 
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used which was adjusted to rats and used to examine the level of alcohol withdrawal 
symptoms (tail stiffness and walking with abnormal/broad gait [211]), as well as locomotor 
(waking), exploration (investigating and rearing), risk assessment (stretch attend posture and 
stretch approach), displacement (grooming) and anxiety-like behaviors (freezing and 
motionless) during 5 minutes of spontaneous behavior. The rats were placed in the center of 
the open field arena (40 x 40 cm) and their behaviors were video-recorded for 5 min using a 
digital camera placed above the cage. The NCT was conducted during the dark phase of the 
light/dark cycle and performed under dim light. The frequency (how often the behavior 
occurs) and duration (total time of an occurrence) of the behaviors were recorded with 
EthoLog® [212].  
In paper I, the effects of OSU6162 treatment on alcohol withdrawal symptoms were 
examined. The data from the NCT did not pass the tests for normality and were therefore 
analyzed using non-parametric analyses. The overall main effect was determined using 
Kruskal-Wallis test and followed by post hoc analyses with Mann Whitney-U test. 
3.4.3 Operant Alcohol Self-administration 
The operant self-administration model is commonly used to measure alcohol intake and the 
motivation to seek alcohol [180]. The operant self-administration procedure was based on 
previous studies showing that rats readily self-administer 20% alcohol without the use of 
sucrose fading or any other initiation procedure [175, 213]. The operant self-administration 
training was conducted in standard Med Associates self-administration chambers. Each 
chamber was equipped with two levers. Lever presses on the active lever activate the pump, 
whereas lever presses on the inactive lever had no programmed consequences. During 
training, rats earned alcohol at a volume of 0.1 ml paired with a discrete tone-light cue. In 
addition, an olfactory cue (orange scent) predictive of alcohol was also used. In the end of the 
training, rats earn alcohol during 60 min sessions (FR 3 schedule of reinforcement) 3 days a 
week (Monday, Wednesday and Friday). During testing, a PR schedule of reinforcement was 
used to determine the rats’ willingness to work for alcohol [181]. The PR method was 
adapted from [214] and the number of lever presses required for one alcohol delivery 
increased within the session according to a pre-defined exponential function [215]. Total 
number of lever presses established in the last successfully completed ratio during the session 
was defined as the breakpoint [181]. 
In Paper I, the effects of OSU6162 on self-administration using a PR schedule of 
reinforcement were evaluated. The PR test data were analyzed using repeated measures 
ANOVA with the within-subjects factor of OSU6162 treatment (0, 15, and 30 mg/kg). 
3.4.4 Cue-induced Reinstatement 
The reinstatement model [196] is a commonly used model to study reinstatement (relapse) of 
drug-seeking behavior [193]. In the cue-induced reinstatement experiment, rats are trained to 
self-administer 20% alcohol as described in 3.4.3. Following the alcohol self-administration 
training, rats were exposed to extinction sessions. During extinction sessions, responses on 
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the previously active lever were not reinforced with alcohol or the activation of the discrete 
tone-light cue. After extinction of lever-pressing, rats were tested for cue/priming-induced 
reinstatement of alcohol seeking. During testing, responding on the active lever led to 
contingent presentations of the tone-light cue previously paired with alcohol delivery but not 
alcohol [216]. A small amount of alcohol was presented in the liquid dispenser as an 
additional cue, or priming at the start of the session; however, no additional alcohol was 
delivered. 
In paper I, the effects of OSU6162 treatment on cue/priming-induced reinstatement of 
alcohol seeking were examined. The reinstatement data were analyzed using an ANOVA 
with the between-subjects factor of treatment (0 and 30 mg/kg). 
3.4.5 The Alcohol Deprivation Model 
The alcohol deprivation model is a relapse-like drinking model and is based on the 
observation of a temporary rise in alcohol intake following a period of forced abstinence 
[194], a so-called ADE. Rats were drinking alcohol in the home-cage using the IA20E model 
for approximately 10 weeks and were thereafter subjected to an abstinence period of 18 days. 
Following the abstinence period, the alcohol bottles were reintroduced and measurements of 
alcohol intake, preference for alcohol over water, water intake and total fluid intake were 
taken. Bottles were weighed both 4 and 24 h after the fluids were presented. 
In Paper III: The effects of OSU6162 to attenuate the ADE were evaluated. The data from the 
ADE test were analyzed using paired Student’s t-test. Prior to the trial it was planned to 
compare difference before and after abstinence period within each treatment group. 
3.4.6 Conditioned Place Preference (CPP) 
The CPP model [217] is a classical model of drug reward, in which laboratory animals are 
trained to associate one distinct compartment (context) with drug injections and a second 
compartment with injections of vehicle [218]. 
The CPP experiments was carried out as described previously [219]. The CPP-boxes 
consisted of two compartments separated by a guillotine door, and with distinct visual and 
tactile cues. The CPP experiments consisted of three phases: pre-conditioning (day 1; 15 
min), conditioning (day 2–5; 60 min/session), and post-conditioning test (day 6; 15min). The 
initial side preference (i.e. the side where the rat spends more than 50% of the time) was 
determined during the preconditioning phase. During the conditioning phase (guillotine door 
closed), each rats received two injections per day with six hours in between, using a biased 
procedure (i.e. drugs were paired with the least preferred compartment and vehicle with the 
preferred compartment). Four conditioning sessions were chosen as three to four sessions are 
generally used to obtain robust CPP to rewarding substances in rodents [220, 221]. Control 
rats were paired with vehicle on both sides. During the post-conditioning test, rats were again 
given free access to both compartments and time spent in each compartment was measured 
during 15 min. Expression of CPP was evaluated by comparing time spent in the drug-paired 
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compartment during post-conditioning, with time spent in the same compartment during pre-
conditioning. 
In paper II, the effects of OSU6162 with regards to abuse liability were evaluated. The CPP 
data were analyzed using paired Student’s t-test within each treatment group as determined a 
priori. 
3.4.7 5-Choice Serial Reaction Time Task (5CSRTT) 
The 5CSRTT paradigm measures motor impulsivity and attention [222]. Rats are trained in 
standard Med Associate chambers. Each chamber had a pellet dispenser on the right wall and 
five nose-poke holes on the left wall. The 5CSRTT procedure was performed as described 
previously [223] except that a modified training protocol was used. This training protocol is 
described in detail in Paper III (Table 1). Briefly, rats are trained to respond to a brief visual 
stimulus presented randomly in one of five nose-poke holes. Correct response (i.e. response 
in an illuminated hole) is rewarded with a food pellet. No reward is given upon incorrect 
response (i.e. response in a non-illuminated hole), omission (no response when starting a 
trial) or premature response (responding before presentation of the visual stimulus). Each 
session is terminated after 100 trials or 40 min, whichever occurred first. The number of 
premature responses is used as a measurement of impulsive behavior [222]. The number of 
premature responses, trials, correct responses, omissions, latency to respond (i.e. time 
between stimulus onset and nose poke) and latency to collect (i.e. time to collect the pellet 
followed a correct response) were recorded. 
In Paper III, the effects of OSU6162 on motor impulse behavior were examined. The 
5CSRTT data were analyzed using repeated-measures ANOVA with the within-subjects 
factors of treatment (baseline, 0, 15 and 30 mg/kg) and condition (ITI-5s and ITI-7s session). 
Baseline was defined as mean of responding during the week before the first OSU6162-
testing. 
3.4.8 Intravenous Self-administration of Oxycodone 
To enable intravenous (iv) self-administration, a catheter was inserted into the right jugular 
vein as described elsewhere [224, 225] and in Paper IV. Rats were trained and tested in 
standard Med Associates self-administration chambers. Each chamber had two levers on 
opposing walls. Lever presses on the retractable active lever activated the infusion pump, 
whereas lever presses on the non-retractable inactive lever had no programmed 
consequences. Rats were trained to self-administer oxycodone (6 h/day) at a dose of 0.1 
mg/kg for 5 days. During training and testing, rats earned oxycodone infusions at a volume of 
65 μl paired with a discrete tone-light cue under a FR 1 schedule of reinforcement. 
In Paper IV, the effects of OSU6162 on oxycodone self-administration were tested. The self-
administration data were analyzed using repeated measures ANOVA with the within-subjects 
factor of OSU6162 dose (0, 7.5, 15, 30 mg/kg). 
 30 
3.4.9 Context-induced Reinstatement 
In humans, relapse is often triggered by exposure to environments previously associated with 
the drug [226]. This phenomenon is modeled in rats using the ABA renewal model [227]. In 
this model, rats are first trained to self-administer a drug in one context (A) and then lever 
pressing is extinguished by placing the rat in a different environment (B). During testing, re-
exposure to the initial environment (A) leads to context induced-reinstatement of drug 
seeking [208]. 
The self-administration chambers were modified to two contexts that differed from each other 
in terms of their auditory (fan on/off), visual (houselight white/red light) and tactile 
(narrow/wide grid) cues [209, 228]. The contexts are referred to as A and B, where A is the 
oxycodone self-administration (training) and reinstatement (testing) context and B is the 
extinction context. Both contexts had two levers on opposing walls as described in 3.4.8. Rats 
were trained to self-administer oxycodone in context A for 6 h/day for 14 days. During 
training, rats earned oxycodone infusions at a volume of 65 μl paired with a discrete tone-
light cue under a FR 1 reinforcement schedule. Oxycodone was infused at a dose of 0.1 
mg/kg/infusion for the first seven sessions and at the dose of 0.05 mg/kg/infusion for the last 
seven sessions. Following the oxycodone self-administration training, rats were exposed to 
extinction sessions (6 h/day). During these sessions, responses on the previously active lever 
led to contingent presentations of the discrete tone-light cue, but were not reinforced with 
oxycodone. After extinction of lever-pressing in context B, rats were tested for context-
induced reinstatement under extinction conditions (lever presses led to the presentation of the 
tone-light cue but not oxycodone). 
In paper IV, the effects of OSU6162 on context-induced reinstatement of oxycodone seeking 
were examined. The reinstatement data were analyzed using a repeated measures ANOVA 
with the within-subjects factors of OSU6162 dose (0 and 15 mg/kg), and Context (A and B).   
3.5 STATISTICS 
The statistics used for the different experiments in this thesis are described under each 
method above. IBM SPSS statistics (version 20.0, SPSS Inc., Chicago, Illinois) or GraphPad 
Prism (GraphPad Software, La Jolla, CA, USA) were used to perform all statistical analyses. 
For all analyses a P-value of <0.05 was considered significant. 
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4 RESULTS 
4.1 PAPER I: THE DOPAMINE STABILIZER (-)-OSU6162 ATTENUATES 
VOLUNTARY ETHANOL INTAKE AND ETHANOL-INDUCED DOPAMINE 
OUTPUT IN THE NUCLEUS ACCUMBENS 
The purpose of this study was to evaluate OSU6162’s potential as a novel treatment for AUD 
using several well-established animal models. We hypothesized that OSU6162 might have 
the ability to stabilize DA activity during acute alcohol drinking and abstinence, which 
potentially may decrease alcohol intake, attenuate alcohol craving, dampen withdrawal 
symptoms, and prevent relapse to alcohol drinking. 
4.1.1 Effects of Acute OSU6162 Treatment on Voluntary Alcohol Intake 
The effects of OSU6162 on alcohol consumption was first evaluated in a group of rats 
voluntary consuming moderate amounts of alcohol (2.9 ± 0.3 g/kg/24 h; n = 9) and 
subsequently in a second group of rats that voluntary emerged in to high (4.6 ± 0.3 g/kg/24 h; 
n = 7) and low (1.9 ± 0.2 g/kg/24 h; n = 6) alcohol consumers. After at least 3 months of 
home-cage alcohol consumption, rats were given an injection of vehicle or OSU6162 (0, 15, 
and 30 mg/kg) once a week in a counterbalanced order, using a within-subjects design. The 
results showed that both OSU6162 doses significantly decreased alcohol intake compared 
with vehicle in rats that had voluntary consumed high levels of alcohol (Fig. 2C). In the 
moderate alcohol consuming rats (Fig. 2B), only the higher OSU6162 dose significantly 
decreased voluntary alcohol intake. In contrast, OSU6162 treatment had no effect in low 
alcohol consuming rats (Fig. 2A). 
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Fig. 2. Acute OSU6162 treatment decreased alcohol intake in moderate and high alcohol consuming rats. 
All rats had voluntarily consumed 20% alcohol in the home-cage for at least 3 months before being subjected to 
acute OSU6162 treatment (0, 15, 30 mg/kg, sc). Each rat received all doses in a counterbalanced order. Both 
OSU6162 doses significantly decreased alcohol intake in the rats voluntarily consuming high amounts of alcohol 
(C; n = 7). A significant reduction in alcohol intake was found only after treatment with the higher OSU6162 
dose in rats consuming moderate amounts of alcohol (B; n = 9). However, OSU6162 treatment had no 
significant effect in the rats voluntary consuming low levels alcohol (A; n = 6). All values are expressed as mean 
± SEM, *p < 0.05; **p <0.01; ***p <0.001 compared with corresponding vehicle at the 24 h time-point. 
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4.1.2 Effects of Repeated OSU6162 Treatment on Alcohol Intake 
Next, the high alcohol-consuming rats were after the last acute OSU6162-administration 
given 3 additional weeks of voluntary alcohol consumption (4.6 ± 0.3 g/kg/24; n = 7) 
Thereafter, half of the rats were given a daily injection of OSU6162 (30 mg/kg) during 8 days 
(Mon-Fri plus Mon-Wed) and the remaining half received vehicle. Following 2 weeks of 
voluntary alcohol consumption, the experiment was repeated with the assigned dose reversed. 
The results showed that repeated OSU6162 treatment significantly decreased alcohol intake 
for all five alcohol-drinking sessions without inducing any tolerance or rebound increase in 
alcohol intake after the treatment was ended in high alcohol consuming rats (Fig 3A). 
Moreover, repeated OSU6162 treatment significantly increased the water intake (Fig. 3B) for 
all five alcohol-drinking sessions. In addition, repeated OSU6162 treatment showed a 
significantly decreased preference for alcohol over water (Fig. 3C) as a result from the 
OSU6162-induced decrease in alcohol intake and increase in water intake. Finally, there was 
no significant effect on the total fluid intake or on the water intake on the 3 days when 
alcohol was not present (data not shown). 
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Fig. 3. Repeated OSU6162 treatment selectively reduced voluntary alcohol intake and preference. The rats 
(n = 7) had been consuming high amounts of alcohol for approximately 5 months before the repeated OSU6162 
treatment was initiated. Each rat received both OSU6162 (30 mg/kg, sc) and vehicle treatment in a 
counterbalanced order. The repeated OSU6162 treatment significantly decreased alcohol intake (A) and 
increased the water intake (B) for all five alcohol sessions. Consequently, the preference for alcohol over water 
was decreased (C). When the repeated OSU6162 treatment was terminated, the alcohol intake (A), the 
preference for alcohol over water (C) and the water intake (B) immediately went back to baseline. All values are 
expressed as mean ± SEM, *p < 0.05; **p <0.01; ***p <0.001 compared with vehicle at the corresponding 
treatment day (4 h time-point). 
4.1.3 Effects of OSU6162 Treatment on Alcohol Withdrawal Symptoms 
Rats (n=20) voluntary consumed high amounts of alcohol in the home-cage using the IA20E 
model for approximately 5 months and were thereafter divided into two groups with equal 
baseline alcohol consumption. After 23 hours of abstinence (acute abstinence), the rats got an 
injection of OSU6162 (30 mg/kg) or vehicle, before being subjected to an open field arena 
(40 x 40 cm) and video-recorded for 5 min. The effect of OSU6162 on alcohol withdrawal 
symptoms (tail stiffness and walking with broad gait [211]) was evaluated. The test was 
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repeated after additional 2 weeks of abstinence (protracted abstinence). As a control for the 
alcohol-induced withdrawal symptoms, one group of alcohol-naïve rats (n = 16) were 
subjected to the NCT but did not receive any pharmacological treatment. The result showed 
that OSU6162 treatment significantly attenuated acute alcohol withdrawal symptoms (Fig. 4) 
but had no significant effect on alcohol withdrawal symptoms after protracted abstinence 
(data not shown). 
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Fig. 4. OSU6162 treatment attenuated acute alcohol withdrawal symptoms. The effects of OSU6162 on 
alcohol withdrawal symptoms (tail stiffness and walking with abnormal broad gait) were evaluated in rats that 
had voluntarily consumed high amounts of alcohol for approximately five months before the test. The frequency 
of both tail stiffness (A) and walking with broad gait posture (B) was significantly increased in both OSU6162 
and vehicle treated animals compared to alcohol-naïve rats. During acute alcohol withdrawal OSU6162 
treatment significantly attenuated the alcohol withdrawal symptoms compared to vehicle. All values are 
expressed as median and range, *p < 0.05; **p < 0.01; ***p < 0.001 compared to corresponding vehicle or as 
indicated. Alcohol-naïve rats (n = 16), vehicle (n = 10) and OSU6162 (n = 10). 
4.1.4 Effects of OSU6162 on Cue/Priming-induced Reinstatement  
Following 6 months of operant alcohol self-administration training, the alcohol seeking 
behavior was extinguished without the presence of the cues. After extinction of lever-
pressing, half of the rats received OSU6162 (30 mg/kg; n=10) and the other half vehicle 
(n=9), 60 minutes before the start of the cue/priming-induced reinstatement test. During the 
test session, the cues were reintroduced in the chambers and as an additional cue, or priming, 
a small amount of alcohol was presented in the liquid dispenser at the start of the session; 
however, no additional reward was delivered. The numbers of active lever presses were 
compared following OSU6162 and vehicle pre-treatment. The results showed that OSU6162 
has the ability to attenuate cue/priming-induced reinstatement of alcohol seeking (Fig. 5A) in 
rats that had been exposed to alcohol for a long period of time. 
4.1.5 Effects of OSU6162 on Alcohol Self-administration   
After the cue/priming-induced reinstatement test the rats went back on regular self-
administration training (FR 3 schedule of reinforcement) for a month. Next, the effect of 
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OSU6162 on alcohol-seeking was evaluated using a PR schedule of reinforcement, where the 
delivery of 20% alcohol was contingent on a visual and auditory cue. The PR test was 
performed once a week during 3 weeks and each rat received both OSU6162 doses (15 and 
30 mg/kg) and vehicle in a counterbalanced order. Active lever presses and breakpoint were 
compared between OSU6162 and vehicle. The results revealed that OSU6162 attenuated 
operant alcohol self-administration under a PR schedule of reinforcement (Fig. 5B) in rats 
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Fig. 5. OSU6162 treatment attenuated cue/priming-induced reinstatement and breakpoint. The effects of 
OSU6162 on cue/priming-induced reinstatement of alcohol seeking and operant self-administration of alcohol 
were examined in rats trained to self-administer 20% alcohol. In the reinstatement test, the cues previously 
associated with the delivery of alcohol were reintroduced. The vehicle-treated rats (n = 10) reinstated their 
alcohol-seeking behavior as shown by a significant increase in the number of active lever press compared with 
the extinction level (A, left panel). The cue/priming-induced reinstatement was significantly attenuated by 
OSU6162 (30 mg/kg; n = 9) treatment (A, right panel). In the progressive ratio test (n = 17), both OSU6162 (15 
and 30 mg/kg) doses significantly decreased the breakpoint (B) compared to vehicle. All values are expressed as 
mean ± SEM, ***p <0.001 
4.2 PAPER II: THE MONOAMINE STABILIZER (-)-OSU6162 COUNTERACTS 
DOWN-REGULATED DOPAMINE OUTPUT IN THE NUCLEUS 
ACCUMBENS OF LONG-TERM DRINKING WISTAR RATS 
In Paper I, we also showed using microdialysis (conducted and analyzed by co-author Björn 
Schilström and the method is described in more details in Paper I) in NAc of alcohol-naïve 
rats, that OSU6162 increased the DA output when given alone. This could possibly indicate 
that OSU6162 has an abuse liability. However, since the OSU6162-induced DA increase was 
rather slow and long lasting in contrast to the rapid peak seen after use of traditional drugs of 
abuse [81, 229], this possibility seems unlikely. Nevertheless, the abuse liability of OSU6162 
has to be further evaluated.  
  35 
4.2.1 Effects of OSU6162 on CPP  
To evaluate the abuse liability of OSU6162, alcohol-naïve rats (n=16) and rats that had been 
drinking alcohol for 3 months (n=15), using the IA20E model, were subjected to the CPP 
model. During conditioning (4 days), rats were injected twice a day with OSU6162 (30 
mg/kg, sc) or vehicle (morning and afternoon), using a biased procedure (i.e. OSU6162 was 
paired with the least preferred compartment and vehicle with the preferred compartment). 
Expression of CPP was evaluated by comparing time spent in the drug-paired compartment 
during post-conditioning, with time spent in the same compartment during pre-conditioning. 
The results showed that OSU6162 did not induce CPP in either the alcohol-naïve rats (Fig. 
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Fig. 6. OSU6162 treatment did not induce CPP. The effects of OSU6162 (30 mg/kg) or vehicle (saline) on 
CPP were evaluated in alcohol-naïve rats (n=16) and rats that had been drinking alcohol for 3 months prior to the 
experiment (n=15). OSU6162 did not induce any significant CPP compared to vehicle in either the alcohol-naïve 
rats (A) or the long-term alcohol drinking rats (B). All values are expressed as mean ± SEM. 
4.3 PAPER III: THE MONOAMINE STABILIZER (-)-OSU6162 PREVENTS THE 
ALCOHOL DEPRIVATION EFFECT AND IMPROVE MOTOR IMPULSIVE 
BEHAVIOR IN RATS 
The purpose of this study was to evaluate the effects of OSU6162 on relapse-like alcohol 
drinking and motor impulsivity. A main problem in the treatment of AUD is the long-lasting 
vulnerability to relapse [191]. Impaired impulsive control, often seen in AUD individuals 
[230], might be one factor contributing to relapse to alcohol drinking [231]. The DA system 
is suggested to be involved in the complex regulation of impulsive behavior [122]. Rodent 
data show that high DA activity in the NAc enhances impulsive behavior, and can be 
attenuated by DA antagonism [232]. In contrast, disrupted activity, presumably DA 
hypoactivity, in prefrontal regions might increase impulsive behavior [233]. Thus, 
neuroanatomically distinct brain regions are linked to different aspects of impulsive behavior, 
and can be modulated by both increase and decrease in DA activity. We therefore 
hypothesized that OSU6162 might have the ability to regulate impulsive behavior, which 
potentially may improve impulse control. 
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4.3.1 Effects of OSU6162 on the ADE 
Following approximately 10 weeks of alcohol drinking in the IA20E model and 18 days of 
forced abstinence, rats were divided in two groups with equal alcohol consumption 
(OSU6162 =3.3±0.3 g/kg/24 h; vehicle=3.2±0.2 g/kg/24 h) based on the last drinking day 
before the abstinence period. On the test day, rats were injected with either OSU6162 (30 
mg/kg) or vehicle (saline), 60 min before the reintroduction of the alcohol. The results 
showed that an ADE was observed in the vehicle treated rats, as shown by a significantly 
increased alcohol intake compared to baseline alcohol drinking. In contrast, OSU6162 
treatment significantly attenuated the ADE as shown by a decreased alcohol intake at the 4 h 
time-point (data not shown) and a non-significant trend towards a reduction in alcohol intake 
at the 24 h time-point (Fig. 7A). Moreover, OSU6162 treatment significantly decreased the 
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Fig. 7. OSU6162 treatment attenuated the ADE. Rats got voluntary intermittent access to alcohol in their 
home-cage during approximately 10 weeks and were thereafter subjected to 18 days of forced alcohol 
abstinence. Prior to the reintroduction of the alcohol, the rats were divided in to two groups with equal baseline 
alcohol consumption and given an injection of vehicle (n=10) or OSU6162 (30 mg/kg; n=6). An ADE was 
observed in vehicle treated rats (A: left panel) but not in rats treated with OSU6162 (A: right panel). Moreover, 
in rats treated with vehicle, a significant increased preference for alcohol was seen (B: left panel), whereas the 
preference for alcohol was significantly reduced in rats treated with OSU6162 (B: right panel). All values are 
expressed as mean ± SEM, *P<0.05; **p <0.01 ***P<0.01; compare to corresponding baseline at the 24 h time-
point. 
4.3.2 Effects of OSU6162 on Motor Impulse Behavior 
Rats were trained in the 5CSRTT for 3-4 months before given access to water (n = 13) or 
alcohol (n = 14) for 7 weeks. Following drinking, an injection of OSU6162 (15 or 30 mg/kg, 
sc) or vehicle (saline) was given to all rats in a counterbalanced order. OSU6162 tests were 
conducted twice a week (Tuesdays and Fridays) every other week, with baseline 5CSRTT 
training sessions on the intervening days. On Tuesdays the rats were tested under an ITI of 5 
s, the same ITI-length used on baseline training. In contrast, on Fridays, the rats were 
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challenged with a prolonged waiting period before presentation of the visual stimulus (ITI 
were changed from 5 to 7 s). This manipulation has been shown to robustly provoke 
premature responses [126]. The results showed that OSU6162 (30 mg/kg) significantly 
improved motor impulsivity in both alcohol-naïve and alcohol drinking rats, as shown by a 
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Fig. 8. OSU6162 treatment attenuated motor impulse control. Following 3-4 months of 5CSRTT-training 
and 7 weeks of home-cage alcohol or water drinking, both alcohol (A) and alcohol-naïve rats (B) significantly 
increased their premature responses compare to baseline when the ITI was prolonged from 5 to 7 seconds in the 
5CSRTT. However, the highest OSU6162 (30 mg/kg) dose significantly reduced the number of premature 
responses compare to vehicle in both alcohol (A) and water (B) pre-exposed rats. All values are presented as 
mean ± SEM, n=13-14 per group; ***p <0.001 compared to corresponding baseline and #p <0.05; compared to 
corresponding vehicle within the ITI-7s- session. 
4.4 PAPER IV: EVALUATION OF THE MONOAMINE STABILIZER (-)-OSU6162 
ON OXYCODONE SELF-ADMINISTRATION AND CONTEXT-INDUCED 
REINSTATEMENT IN RAT 
Finally, we decided to evaluate the effects of OSU6162 on another drug of abuse using iv 
self-administration. The opioid addiction epidemic is ongoing in the US [234]. Drug 
overdoses is the leading cause of accidental death in the US and these overdoses are mostly 
related to prescription pain relievers (such as oxycodone and fentanyl) and heroin [234]. We 
therefore decided to evaluate the potential of OSU6162 as a novel treatment for opioid 
addiction by evaluating the effect of OSU6162 on oxycodone self-administration and 
context-induced reinstatement of oxycodone seeking in rats. The mesolimbic DA system has 
been suggested to contribute to the rewarding effects of opiates [60, 106]. Moreover, a 
decreased activity in NAc have been shown after chronic administration of opiates in rats 
[108]. Despite the large body of evidence of an involvement of the mesolimbic DA system, 
behavioral pharmacological experiments with DA receptor antagonists have shown minimal 
effect on self-administration of opiate agonists, at least in doses that does not cause sedation 
[235, 236]. We hypothesized that OSU6162 might have the ability to stabilize DA activity in 
both the acute and abstinence phase of oxycodone self-administration, which potentially may 
attenuate craving and reinstatement to oxycodone seeking. 
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4.4.1 Effects of OSU6162 on Oxycodone Self-administration 
The effects of OSU6162 on oxycodone self-administration (0.1 mg/kg/infusion) were 
examined in rats trained to self-administer oxycodone. Following oxycodone self-
administration training, rats got 3 days of baseline oxycodone self-administration for 2 h/day 
before the start of the test. Rats were tested (n=9) every other day (within-subjects design) for 
oxycodone self-administration (2 h/day) after pre-treatment with OSU6162 (7.5, 15, and, 30 
mg/kg) or vehicle in a counterbalanced order. The results showed that the two higher doses of 
OSU6162 (15 and 30 mg/kg) significantly decreased oxycodone self-administration 
compared to vehicle (Fig. 9A). 
4.4.2 Effects of OSU6162 on Context-induced Reinstatement  
After extinction of the operant response in context B, the effect of OSU6162 on context-
induced reinstatement of oxycodone seeking in context A were examined. Rats (n = 10) 
received vehicle or OSU6162 (15 mg/kg) in a counterbalanced order using a within subjects 
design. The results showed that exposure to the oxycodone context reinstated active lever 
responding after extinction, but there was no difference between vehicle or OSU6162 
treatment (Fig. 9B). 
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Fig. 9. OSU6162 treatment attenuated oxycodone self-administration but had no effect on context-induced 
reinstatement. Self-administration test (A): Number of oxycodone infusions and active and inactive lever 
responses during the self-administration test sessions with OSU6162. Rats (n = 9) received an injection with 
vehicle or OSU6162 (7.5, 15, and 30 mg/kg, sc) 60 min before the test sessions every other day using a within 
subjects design. Reinstatement test (B): Number of active lever presses in rats (n = 10) tested in the extinction 
and oxycodone contexts after injections of vehicle or OSU6162 (15 mg/kg, sc) before exposure to the oxycodone 
context and the extinction context using a within subjects design. Data are presented as mean±SEM ** p<0.01 
compared to vehicle. 
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5 DISCUSSION 
The main findings in this thesis were that OSU6162 attenuated several alcohol-mediated 
behaviors, including voluntary alcohol consumption, operant alcohol self-administration 
under PR schedule of reinforcement, alcohol withdrawal symptoms, ADE and cue-induced 
reinstatement of alcohol seeking, in rats that had voluntarily consumed alcohol for an 
extended period of time. In addition, OSU6162 decreased motor impulsivity, as measured by 
the 5CSRTT, in both alcohol-naïve and alcohol drinking rats.  
The results in paper I and III highlight four characteristics desirable for an AUD medication. 
First, repeated OSU6162 treatment significantly decreased alcohol intake compared with 
vehicle on each treatment day, indicating that no tolerance to the ability of OSU6162 to 
decrease alcohol intake in rats developed over time. This finding is in agreement with a 
previous study showing maintained anti-dyskinetic effects of OSU6162 in a primate model of 
Parkinson’s disease [237]. Second, there was no marked rebound increase in drinking when 
the OSU6162 treatment was terminated. However, the rapid return to baseline drinking after 
the treatment indicates that continuous OSU6162 treatment might be needed to control 
drinking in a clinical situation. Third, OSU6162 attenuated cue-induced reinstatement, 
relapse-like alcohol drinking (ADE) and blunted acute alcohol withdrawal symptoms, which 
indicates that OSU6162 might have potential to prevent relapse triggered by alcohol craving, 
re-exposure to alcohol, alcohol related cues, and/or an urge to relieve abstinence symptoms. 
Fourth, OSU6162 improved motor impulsivity, which indicate that OSU6162 might have 
beneficial effects on cognitive functions including impulse control. A characteristics desirable 
for a potential AUD medication because AUD individuals often suffer from cognitive 
impairments [117, 118]. 
The results in Paper I showed that OSU6162 significantly decreased voluntary alcohol intake 
in rats consuming moderate and high amounts of alcohol, whereas there was no significant 
effect in rats consuming low amounts of alcohol. The reason for the diverse results of acute 
OSU6162 treatment between the three groups is not fully understood, but we hypothesize that 
the long-term consumption of high and moderate amounts of alcohol might have induced 
changes in the DA system, rendering these rats more sensitive to the effects of OSU6162. 
This hypothesis is supported by early animal studies showing a downregulation of D2-
receptors [109] and a marked reduction in extraneural DA output [238] in the mesolimbic DA 
system after chronic alcohol consumption. Furthermore, a recent study, using the IA20E 
model, showed a significantly reduced DA output in the NAc in rats that had been drinking 
high amounts of alcohol for 7 weeks compared with alcohol-naïve rats [183]. In addition, in 
our microdialysis study, in Paper II, we showed that long-term voluntary alcohol drinking for 
10 months significantly reduced DA output in the NAc compared to alcohol-naïve rats. 
Moreover, the alcohol-induced DA-peak was blunted and there was a subsequent shift in DA 
levels below baseline in the long-term drinking compare to the alcohol-naïve rats. Thereby, it 
is possible that OSU6162 treatment presumably decrease alcohol intake in high and moderate 
consuming rats by normalize their possible hypodopaminergic state and leave the low alcohol 
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consuming rats unaffected due to their assumed already “normal” or less affected DA system. 
This idea is supported by the microdialysis experiment in Paper II, where OSU6162-
pretreatment normalized the alcohol-induced DA-peak and prevented the DA levels to dip 
below baseline in alcohol drinking rats. Finally, the diverse results, following acute OSU6162 
treatment in low, moderate, and high drinkers, give further support for OSU6162 ability to 
stimulate, suppress, or show no effect on DA-related behaviors depending on the prevailing 
dopaminergic tone [138, 146, 147]. 
The mechanism behind the findings of attenuated alcohol self-administration, alcohol 
withdrawal symptoms, cue-priming induced reinstatement and ADE following OSU6162 
treatment is not fully understood. The mesolimbic DA system is impaired upon cessation of 
chronic alcohol use and this decreased function are hypothesized to contribute to alcohol 
withdrawal symptoms and the switch from positive to negative reinforcement [51, 52, 60]. 
Indeed, a downregulated DA system has been demonstrated in both humans and rodents 
during alcohol withdrawal [109-112, 238]. As maintained above, in our microdialysis study, 
we showed that long-term alcohol drinking in the IA20E model, induced DA deficits in NAc 
compare to alcohol-naïve rats. Moreover, OSU6162 treatment normalized the alcohol-
induced DA-peak and counteracted this hypodopaminergic state. Thus, OSU6162 treatment 
might attenuate alcohol withdrawal symptoms by normalizing alcohol-induced DA deficits. 
Moreover, previous studies have demonstrated that alcohol self-administration and even the 
anticipation of alcohol availability produces a rise in DA levels in the NAc in rats [87]. 
Therefore, the mechanism of OSU6162 to attenuate alcohol self-administration, cue/priming-
induced reinstatement and ADE might be to act as an antagonist and decrease the possible 
increased level of DA back to baseline. Thus, OSU6162 might have decreased the positive 
reinforcing effects of alcohol during the PR test, as well as decreased the alcohol seeking 
induced by environmental stimuli previously associated with alcohol.  
In paper I, we also conducted a battery of control experiments to evaluate the specificity of 
the effects observed after OSU6162 administration on alcohol-mediated behavior. These 
control experiment showed that OSU6162 i) was more efficacious than the currently 
available FDA-approved AUD medication naltrexone in decreasing voluntary alcohol intake, 
ii) had no significant effect on voluntary intake of a salty solution, iii) significantly decreased 
the intake of a sucrose solution, iv) and had no effect on general motor activity. The 
unaffected general motor activity and intake of a salty solution indicate that rats following 
OSU6162 treatment have an intact general motor activity. This idea is in agreement with 
previous findings showing no general motor impairments of OSU612 using the same dose-
range [138, 146] as in this thesis. The lack of motor impairments is further supported by the 
increased water intake in IA20E model following acute and repeated OSU6162 treatment 
(Paper I). Moreover, in paper I, we also revealed a lack of significant effect on inactive lever 
pressing in the PR-experiment and an increased response on the inactive lever during cue-
induced reinstatement. In addition, using the 5CSRTT, we found that the latency to respond 
and to collect the reward following OU6162 treatment was unaffected (Paper III). Together 
these results provide support for an intact general motor activity and confirm the capacity of 
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that rats to perform the operate task as well as drink the alcohol solution. The finding that 
OSU6162 decreased intake of a sucrose solution, had no effect on intake of a salty solution or 
water when alcohol was not present, indicating that the effects of OSU6162 might be 
selective for intake of substances with highly reinforcing properties. In fact, sucrose has been 
shown to be a powerful reinforcer in rats [239]. This idea is further supported by the control 
experiment in paper IV, showing that OSU6162 decreased self-administration of palatable 
food pellets, which have previously been shown to be highly rewarding in rats and strongly 
preferred over both methamphetamine [224, 225] and heroin [240]. The control experiment 
with naltrexone, showed that OSU6162 might be superior to naltrexone from some aspects. 
Specifically, naltrexone-treated rats decreased both their alcohol intake and total fluid intake. 
In contrast, the OSU6162-treated rats compensated the loss in fluid intake from the decreased 
alcohol intake with an increased water intake, resulting in a maintained total fluid intake. 
In Paper III, we found that OSU6162 improved motor impulsivity in both alcohol-naïve and 
alcohol drinking rats as measured with the 5CSRTT. These results indicate that improvement 
of motor impulse control might be one mechanism behind OSU6162’s ability to blunt 
relapse-like behavior such as the ADE and cue/priming-induced reinstatement of alcohol 
seeking in long-term drinking rats. In the 5CSRTT experiment, OSU6162 treatment also 
induced a trend towards an increased omission rate, decreased correct responding and number 
of trials, possibly indicating a sedative effect. However, the unaffected latency to respond and 
to collect the reward following treatment even with the highest OSU6162 (30 mg/kg) dose 
indicates an intact motor activity and suggests that sedation is not the reason for the decreased 
premature responding. The lack of sedative effect is also supported by the control 
experiments in Paper I (discussed above), showing that OSU6162 (30 mg/kg) had no effect 
on general motor activity or intake of a salty solution. We therefore hypothesize that the 
increased omission rate, decreased correct responding and number of trials following the 
OSU6162 treatment in the 5CSRTT might indicate a decreased motivation to seek the reward 
(i.e. palatable food pellets) which is expressed as a decreased performance during the 
5CSRTT. This suggestion is supported by our control experiment in Paper IV, in which 
OSU6162 significantly attenuated intake of this food pellets in an operant self-administration 
procedure. In addition, as mentioned above, these food pellets are strongly preferred over 
both methamphetamine [224, 225] and heroin [240] in rats. 
In regards to OSU6162's potential therapeutic applicability in a patient population with AUD, 
it should be noted that we also showed in Paper I and II, using microdialysis, that OSU6162 
increased the DA output in NAc in both alcohol-naïve and long-term alcohol drinking rats. 
This could possibly indicate that OSU6162 has an abuse liability. However, since the 
OSU6162-induced DA increase was rather slow and long lasting in contrast to the rapid peak 
seen after use of traditional drugs of abuse [81, 229], this possibility seems unlikely. This 
suggestion is supported by the results in paper II showing that OSU6162 did not induce CPP 
in either the alcohol-naïve rats or rats that had been drinking alcohol for three months before 
the start of the experiment. These results indicate that OSU6162 is not rewarding on its own 
and most likely does not possess any abuse liability. 
 42 
In Paper IV, our preliminary results showed that OSU6162 attenuated self-administration of 
oxycodone but had no effect on context-induced reinstatement of oxycodone seeking. 
Previous, behavioral pharmacological experiments with DA receptor antagonists have shown 
minimal effect on self-administration of opiate agonists, at least in doses that does not cause 
sedation [235, 236]. However, the decreased self-administration of oxycodone following 
OSU6162 treatment in the present study is in line with a previous study showing that 
tentagrun, a partial DA D2 agonist, attenuated heroin self-administration under both FR- and- 
PR schedule of reinforcement [84]. This is also in agreement with the results in Paper I, 
showing that OSU6162 attenuated alcohol self-administration under a PR schedule of 
reinforcement. Together, the present study and the study by Zhang and colleagues, indicate 
that compounds that are able to buffer the DA activity rather than fully block DA 
transmission might represent novel candidates for pharmacological interventions of drug 
abuse, at least for alcohol and opioids. In Paper IV, we found that rats reinstated to 
oxycodone seeking when placed in their initial (training) environment, but had no ability to 
attenuate this reinstatement. However, we only included one dose of OSU6162 (15 mg/kg) in 
this experiment and it is possible that a higher dose would be needed to attenuate context-
induced reinstatement. Indeed, a higher dose of OSU6162 (30 mg/kg) was used in the 
positive alcohol study on cue/priming-induced reinstatement. Previous studies have shown 
that DA D1 antagonists have the potential to attenuate context-induced reinstatement of 
heroin seeking [241, 242]. However, studies evaluating the role of D2 receptors in context-
induced reinstatement of opiate seeking are limited. Future studies are needed, preferably 
doing a full dose-response curve with OSU6162, include more doses of oxycodone, and a PR 
schedule of reinforcement, to fully evaluate the effects of OSU6162 on oxycodone self-
administration and context-induced reinstatement of oxycodone seeking. 
In conclusion, this thesis show that the monoamine stabilizer OSU6162 has the ability to 
attenuate voluntary alcohol consumption, operant alcohol self-administration, alcohol 
withdrawal symptoms, relapse-like alcohol drinking and cue-induced reinstatement of alcohol 
seeking, in rats that had voluntarily consumed alcohol for an extended period of time. In 
addition, we showed in this thesis that OSU6162 improve motor impulse control, which 
might help AUD individuals to override a compulsive drug-taking behavior in response to 
craving and thereby possibly prevent relapse to alcohol drinking. Based on these findings and 
the favorable side effect profile of OSU6162 [160], a “proof-of-concept” double-blind 
placebo-controlled clinical study in 56 alcohol dependent patients was recently conducted 
[243]. The clinical study was successfully executed and the results support the predictive 
validity of this preclinical evaluation. Specifically, OSU6162, compared to placebo, 
significantly attenuated craving after intake of alcohol and induced significantly lower 
subjective “liking” of the consumed alcohol, effects driven by individuals with high levels of 
baseline impulsivity. Furthermore, none of the patients felt “high” or wanted more of the 
OSU6162-medication when the study was ended [243]. 
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6 SUMMARY AND CONCLUDING REMARKS 
Alcohol use disorder is a common chronic relapse disorder, causing serious medical, 
economic and social consequences. Globally, AUD is among the top five leading causes of 
morbidity and mortality. Despite the major health problem, only four medications are 
approved for treatment of AUD. However, the clinical efficacies of these are limited and new, 
more effective, medications are truly needed. 
As mentioned before, the DA system is one possible treatment target for AUD.  Dopamine D2 
receptors has been suggested to be involved in mediating alcohol’s reinforcing properties and  
a decrease in DA release and a reduction in D2 receptors have been found in detoxified AUD 
patients. This DA down-regulation is hypothesized to induce alcohol craving and contribute 
to relapse even after a long period of abstinence. The fact that OSU6162 might have the 
ability to modulate DA transmission without inducing any severe side effects makes 
OSU6162 unique as a compound with D2 receptor blockage properties. Thus, a great 
advantage of OSU6162 compared to traditional D2 antagonists, might be the lack of 
extrapyramidal reactions. This unique mechanism of action highlights the potential of 
OSU6162 for treatment of a variety of conditions, including AUD, involving dysregulation or 
dysfunction in the DA system. 
In this thesis, we have identified OSU6162 as a potential medication for AUD using validated 
animal models. For example, we showed that OSU6162 attenuated voluntary alcohol 
consumption, operant alcohol self-administration under PR schedule, alcohol withdrawal 
symptoms, cue-induced reinstatement of alcohol seeking and the ADE in rats that have been 
drinking alcohol for an extended period of time. In addition, we found that OSU6162 
treatment improved motor impulse control in both alcohol-naïve rats and alcohol drinking 
rats. Based on these preclinical findings and the favorable side effect profile of OSU6162, a 
“proof-of-concept” double-blind placebo-controlled clinical study in 56 alcohol dependent 
patients was recently conducted. The clinical results confirmed the predictive validity of our 
preclinical evaluation. Specifically, OSU6162 significantly attenuated craving after intake of 
alcohol and induced significantly lower subjective “liking” of the consumed alcohol 
compared to placebo. Interestingly, these effects were driven by individuals with high levels 
of baseline impulsivity. In addition, none of the patients felt “high” or wanted more of the 
OSU6162-medication when the study was ended, giving support for our results in paper II 
showing that OSU6162 did not induce CPP in either the alcohol-naïve rats or rats that had 
been drinking alcohol for a long time. Collectively, these preclinical and clinical results give 
further support for OSU6162 as a novel treatment for AUD and merit for a full-scale 
randomized clinical efficacy trial in AUD patients. A positive outcome of such a study would 
benefit a large patient group that today lack adequate treatment. 
The opioid epidemic is ongoing in the United State and new medications for opioid addiction 
are crucial. We therefore, in paper IV, evaluate the potential of OSU6162 on oxycodone self-
administration and context-induced reinstatement of oxycodone seeking. We found that 
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OSU6162 treatment attenuated operant oxycodone self-administration but had no effect, at 
least in the dose tested, on context-induced reinstatement. The present study is still promising 
and give support for a full preclinical evaluation. 
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